<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673387</url>
  </required_header>
  <id_info>
    <org_study_id>DFA102</org_study_id>
    <nct_id>NCT00673387</nct_id>
  </id_info>
  <brief_title>Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, dose-ranging study to examine the safety,
      tolerability and effect on body weight of a range of doses of metreleptin and pramlintide,
      each administered by a separate subcutaneous (SC) injection in obese and overweight subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable Population</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>Body weight was measured in kilogram (kg). Baseline is defined as Day 1. If Day 1 was missing or after the first dose date of randomized treatment, the last available value prior to Day 1 was used. Drug Randomization stratified by sex and 3 categories baseline BMI (12 arms); 3 treatment arms combined for summaries as single placebo treatment group; 3 combined for summaries as single pramlintide monotherapy treatment group (total: 8 treatment groups).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>Baseline refers to Day 1. If Day 1 value is missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change From Baseline to Weeks 4, 12, 28 in Mean Trough Concentration of Total Leptin - Evaluable Population</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>Mean fasting plasma total leptin concentration (nanograms per milliliter; ng/mL) change from baseline over time by pooled metreleptin dose (sex, baseline BMI category, and baseline value). Baseline defined as Day 1. If Day 1 value is missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 is used. Evaluable population: all participants who received at least one dose of randomized treatment, had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding. Leptin concentrations measured using a validated immunoenzymetric assay utilizing polyclonal capture antibody, monoclonal detection antibody, and colorimetric readout by Amylin Pharmaceuticals, Inc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Absolute Change in Body Weight From Baseline to Weeks 4, 12, and 28 - Evaluable Population</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>Least Squares (LS) mean absolute change in Body weight was measured in kilograms (kg). Baseline is defined as Day 1. If Day 1 was missing or after the first dose date of randomized treatment, the last available value prior to Day 1 was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Change in Waist Circumference From Baseline to Week 12 and Week 28 - Evaluable Population</measure>
    <time_frame>Baseline to Weeks 12 and Week 28</time_frame>
    <description>Waist circumference was measured at baseline (Day 1), Weeks 12, 28 (or at early termination) in centimeters (cm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean of the Total Area Under the Concentration Time Curve (AUC) From Time 0 to Last Quantifiable Concentration (Tlast) for Pramlintide at Weeks 4 and 24 - Evaluable Population Receiving Pramlintide</measure>
    <time_frame>Week 4 and Week 24</time_frame>
    <description>Assessment of AUC was over a period of 2 hours following pramlintide administration. AUC (0 to time of last quantifiable concentration (-tlast). For AUC calculation, concentration at -5 min will be considered as 0 h concentration if quantifiable, otherwise, t=0 h. AUC measured as picograms*hour/milliliter (pg*h/mL). Pramlintide concentrations measured using a colorimetric immunoenzymetric assay employing monoclonal antibodies against pramlintide for both capture and detection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean of AUC From Time 0 to Infinity for Pramlintide at Weeks 4 and 24 - Evaluable Population Treated With Pramlintide</measure>
    <time_frame>Weeks 4 and 24</time_frame>
    <description>Assessment of AUC was over a period of 2 hours following pramlintide administration. Area under the concentration curve (AUC) time 0 to infinity (-inf). For AUC calculations, concentration at -5 min will be considered as 0 h concentration if quantifiable. AUC measured in picograms*hour/milliliter (pg*h/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) for Pramlintide at Weeks 4 and 24 - Evaluable Population Receiving Pramlintide</measure>
    <time_frame>Week 4 and Week 24</time_frame>
    <description>Assessment of Cmax was over a period of 2 hours following pramlintide administration at Weeks 4 and 24. Cmax was measured as picograms/milliliter (pg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Least Squares (LS) Mean Absolute Change From Baseline to Week 28 in Percent of Body Fat - Evaluable Population</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>Parameters of body composition were measured with a Dual Energy X-ray absorptiometry (DEXA) scan and reported as a percent (%). Data from the first valid DEXA scan obtained no later than 7 days after the first randomized dose was considered as valid baseline values; data from the last valid DEXA scan obtained no later than 10 days after last clinical visit or no later than 14 days after last dose of randomized study medication was considered as valid study termination values. Absolute change from baseline was defined as percent body fat at Week 28 - percent body fat at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Absolute Change From Baseline to Week 28 in Total Body Fat Mass (k) - Evaluable Population</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>Parameters of body composition were measured with a Dual Energy X-ray absorptiometry (DEXA) scan. Data from the first valid DEXA scan obtained no later than 7 days after the first randomized dose was considered as valid baseline values; data from the last valid DEXA scan obtained no later than 10 days after last clinical visit or no later than 14 days after last dose of randomized study medication was considered as valid study termination values. Body fat mass was measured in kilogram (k).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Absolute Change From Baseline to Week 28 in Fat-free Mass (kg) - Evaluable Population</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>Parameters of body composition were measured with a Dual Energy X-ray Absorptiometry (DEXA) scan. Data from the first valid DEXA scan obtained no later than 7 days after the first randomized dose was considered as valid baseline values; data from the last valid DEXA scan obtained no later than 10 days after last clinical visit or no later than 14 days after last dose of randomized study medication was considered as valid study termination values. Fat-free mass were measured in kilogram (k).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LS Mean Absolute Change From Baseline to Week 28 in Fasting Plasma Glucose, Total Cholesterol (TC), Triglycerides, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol - Evaluable Population</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>Baseline refers to Visit 5 (Day 1). If Day 1 value is missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 is used. Fasting samples were obtained at baseline, Weeks 4, 12, and 28. All parameters were measured in milligrams per deciliter (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change From Baseline to Week 28 for Insulin - Evaluable Population</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>Baseline refers to Visit 5 (Day 1). If Day 1 value is missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 is used. Fasting samples were obtained at baseline, Weeks 4, 12, and 28. Parameter was measured micro international units per milliliter. (µIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change From Screening to Week 24 in Impact of Weight on Quality of Life Questionnaire-lite Version (IWQOL-Lite) Total Score - Evaluable Population</measure>
    <time_frame>Screening to Week 24</time_frame>
    <description>Subjective effects of weight loss were measured using the IWQOL-Lite questionnaire, a 31-item patient reported outcome (PRO) instrument used to assess the effect of weight on physical function, self-esteem, sexual life, public distress, and work. Individual items have a range of 1 to 5 with 5=always true and 1= never true. The total score for the IWQOL-Lite instrument is measured on a scale from 0 (worst) to 100 (best). Higher scores indicate improvement. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change From Screening to Week 24 in Binge Eating Scale (BES) Total Score - Evaluable Population</measure>
    <time_frame>Screening to Week 24</time_frame>
    <description>The Binge Eating Scale (BES) is a 16-item questionnaire that assesses the behavioral and cognitive correlates of binge eating, including participants' perceived self-control over eating behavior using a range of 1 to 4 with 1=positive perceptions and 4= negative perceptions. The minimum and maximum score for the BES instrument is 0 and 55, respectively. The higher the score the worse the outcome. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change From Screening to Week 24 in Susceptibility to Eating Questionnaire (SEQ) Item Scores - Evaluable Population</measure>
    <time_frame>Screening to Week 24</time_frame>
    <description>The eating questionnaire is an exploratory measure of appetite, satiety, and perceived control over portion size using 10 VAS items with each response measured on a 100 mm visual analogue scale (ranges vary from Never to Very Often; Not at All Difficult to Extremely Difficult; Not at all Strong to Very Strong). Lower scores indicate improvement. The Eating Questionnaire instructed participants to rate their responses to these items over the past 7 days. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change From Screening to Week 24 in Hospital Anxiety and Depression Scale (HADS) Total Scores - Evaluable Population</measure>
    <time_frame>Screening to Week 24</time_frame>
    <description>The HADS is a questionnaire that uses 14 items to assess both anxiety and depression over the past week. The odd numbered items constitute the anxiety subscale, and the even numbered items constitute the depression subscale. The individual response scores for each subscale component are added together to obtain the individual subscale scores. The minimum and maximum score for each subscale is 0 and 21, respectively. The higher the score, the worse the outcome. Values were obtained for this questionnaire on Visit 3 in the screening period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change From Screening to Week 24 in Summary Scores for Profile of Mood States - Brief (POMS-B) - Evaluable Population</measure>
    <time_frame>Screening to Week 24</time_frame>
    <description>The POMS is a mood scale consisting of 65 mood adjectives that assess participants' mood over the past seven days. The POMS-B is an authorized, 30-item brief version of the POMS consisting of five items for each of the six POMS factors. The mood adjectives load onto 6 mood factors, which are as follows: Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment. Scores range from 0= Not at All to 4=Extremely. The factor scores are added to obtain the total mood disturbance score. A lower total mood disturbance score indicates improvement. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change From Screening to Week 24 in Minutes to Fall Asleep, Hours of Sleep and The Pittsburgh Sleep Quality Index (PSQI) Global Score - Evaluable Population</measure>
    <time_frame>Screening to Week 24</time_frame>
    <description>The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire which assesses sleep quality and sleep disturbances over a period of 1 month. The PSQI provides ratings on seven domains of sleep (subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction). The sum of the individual domains yields a global sleep quality score with a range of 0-21. A PSQI score &gt;5 is indicative of poor sleep, which is characterized by severe difficulties in at least two domains, or moderate difficulties in three or more domains. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change From Screening to Week 24 in the Epworth Sleepiness Scale (ESS) Total Score - Evaluable Population</measure>
    <time_frame>Screening to Week 24</time_frame>
    <description>The Epworth Sleepiness Scale (ESS) is an eight-item questionnaire that assesses sleep propensity in daily situations of increasing sleepiness on a four-point scale with 0=would never doze and 3=high chance of dozing. Lower scores indicate improvement. Values were obtained for this questionnaire on Visit 3 in the screening period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hematology and Urinalysis Laboratory Values of Potential Clinical Importance Observed From Screening to Week 28 - Intent to Treat Population</measure>
    <time_frame>Screening to Week 28</time_frame>
    <description>Criteria for laboratory values of potential clinical importance for obese and overweight (BMI &gt;= 25 kg/m^2) participants: Platelets high (H) &gt;500,000/µL; low (L) &lt;75,000/µL. Hematocrit males &lt;36%, females &lt;30%. Hemoglobin males &lt;12 g/dL, females &lt;10 g/dL. White blood cell count (WBC) H &gt;18,000/µL; L &lt;1,500/µL. Urine protein H &gt;= 3+ or &gt;= 500 mg/dL. Urine glucose H &gt;= 3+ or &gt;= 500 mg/dL. Urine ketones &gt;= 3+ or Large. Values obtained at Screening, Day -7, Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28. Numbers of values are cumulative across the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Chemistry Laboratory Values of Potential Clinical Importance Observed From Screening to Week 28 - Intent to Treat Population</measure>
    <time_frame>Screening to Week 28</time_frame>
    <description>Obtained at: Screening, Days -7, 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28. Numbers of laboratory values are cumulative across the study. Criteria for values of potential clinical importance for obese and overweight (BMI&gt;=25 kg/m^2) participants: Total bilirubin High (H) &gt; 2 mg/dL; Plasma/serum glucose fasting or non-fasting H &gt; 200 mg/dL, low (L) &lt; 60 mg/dL; Albumin L &lt;2.5 g/dL; Creatine kinase H &gt; 3*Upper limit of Normal (ULN); Sodium L &lt;130 milliequivalents per liter (mEq/L), H &gt; 150 mEq/L; potassium L&lt;3.0 mEq/L, H&gt; 5.5 mEq/L;bicarbonate L&lt;18 mEq/L, H&gt;35 mEq/L;calcium L &lt;8mg/dL, H&gt; 11 mg/dL; triglycerides H&gt; 500 mg/dL; Cholesterol L &lt; 100 mg/dL, H &gt; 350 mg/dL; Alkaline phosphatase H &gt; 3*ULN; Gamma-glutamyltransferase H&gt;3*ULN; creatinine males &gt; 1.6 mg/dL, females &gt; 1.4 mg/dL; alanine aminotransferase H &gt; 3*ULN; aspartate aminotransferase H &gt; 3*ULN; urea nitrogen H &gt; 45 mg/dL; uric acid males &gt; 10.0 mg/dL, females &gt; 8.0 mg/dL; Phosphorus L &lt; 1.0 mg/dL H &gt; 6.0 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Systolic and Diastolic Blood Pressure From Baseline to Week 28 - Intent to Treat Population</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>Baseline refers to Day 1. If Day 1 value was missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 was used. Blood pressure was taken while the participant was sitting and was measured in millimeters of mercury (mm Hg). Values obtained at Screening, Day -7, Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Heart Rate From Baseline to Week 28 - Intent to Treat Population</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>Baseline refers to Day 1. If Day 1 value was missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 was used. Heart rate was measured while the participant was sitting and was measured in beats per minute (bpm). Values obtained at Screening, Day -7, Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Positive Anti-leptin Antibody Titers at Week 28 - Intent to Treat Population</measure>
    <time_frame>Baseline to Week 28</time_frame>
    <description>Baseline refers to Day 1. If Day 1 value was missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 was used. Serum titer determinations for antibodies to metreleptin were made using a validated electrochemical luminescence (ECLA) bridging assay. Antibody titers were assessed according to the following dilutions: 0, 5, 25, 125, 625, 3125, 15625, and 78125. Participants were considered to have a positive titer to treatment-emergent antibodies to metreleptin at a given visit if they had a titer &gt;=5 following a negative or missing titer at baseline or if they had a titer that had increased by at least 2 dilutions from a detectable level at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening to Week 28 in Electrocardiogram Parameters - Intent to Treat Population</measure>
    <time_frame>Screening to Week 28 (or study termination)</time_frame>
    <description>A 12-Lead electrocardiogram (ECG) was obtained at Screening, Day 1, Weeks 1, 12, 28 (study termination). The PR interval, which is time from beginning of the P wave to the beginning of the QRS complex (Note: QRS complex is a name for the combination of 3 of the graphical deflections seen in an ECG); QRS interval (time from the beginning to the end of the QRS complex); QT interval (measure between Q wave and T wave in the heart's electrical cycle); and QT interval corrected for heart rate using Fridericia's formula (QTcF) were measured in milliseconds (msec).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Screening to Week 28 in the Electrocardiogram Parameter of Heart Rate - Intent to Treat Population</measure>
    <time_frame>Screening to Week 28 (or early termination)</time_frame>
    <description>A 12-Lead electrocardiogram (ECG) was obtained at Screening (visit 2), Day 1, Weeks 1, 12, 28 (study termination). Heart Rate was measured in beats per min (bpm).</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">636</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo-P + Placebo-M</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to pramlintide BID plus placebo matched to metreleptin BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pramlintide 360 mcg + Placebo-M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>360 mcg pramlintide given twice per day (BID) plus Placebo matched to Metreleptin given BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-P + Metreleptin 5.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo matched to pramlintide BID plus metreleptin 5.0 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pramlintide 180 mcg + Metreleptin 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pramlintide 180 mcg BID plus Metreleptin 2.5 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pramlintide 180 mcg + Metreleptin 5.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pramlintide 180 mcg BID plus Metreleptin 5.0 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pramlintide 360 mcg + Metreleptin 1.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pramlintide 360 mcg BID plus Metreleptin 1.25 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pramlintide 360 mcg + Metreleptin 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pramlintide 360 mcg BID plus Metreleptin 2.5 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pramlintide 360 mcg + Metreleptin 5.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pramlintide 360 mcg BID plus Metreleptin 5.0 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pramlintide acetate</intervention_name>
    <description>subcutaneous injection, twice a day</description>
    <arm_group_label>Pramlintide 360 mcg + Placebo-M</arm_group_label>
    <arm_group_label>Pramlintide 180 mcg + Metreleptin 2.5 mg</arm_group_label>
    <arm_group_label>Pramlintide 180 mcg + Metreleptin 5.0 mg</arm_group_label>
    <arm_group_label>Pramlintide 360 mcg + Metreleptin 1.25 mg</arm_group_label>
    <arm_group_label>Pramlintide 360 mcg + Metreleptin 2.5 mg</arm_group_label>
    <arm_group_label>Pramlintide 360 mcg + Metreleptin 5.0 mg</arm_group_label>
    <other_name>Smylin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metreleptin</intervention_name>
    <description>subcutaneous injection, twice a day</description>
    <arm_group_label>Placebo-P + Metreleptin 5.0 mg</arm_group_label>
    <arm_group_label>Pramlintide 180 mcg + Metreleptin 2.5 mg</arm_group_label>
    <arm_group_label>Pramlintide 180 mcg + Metreleptin 5.0 mg</arm_group_label>
    <arm_group_label>Pramlintide 360 mcg + Metreleptin 1.25 mg</arm_group_label>
    <arm_group_label>Pramlintide 360 mcg + Metreleptin 2.5 mg</arm_group_label>
    <arm_group_label>Pramlintide 360 mcg + Metreleptin 5.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo-P</intervention_name>
    <description>subcutaneous injection, twice a day</description>
    <arm_group_label>Placebo-P + Placebo-M</arm_group_label>
    <arm_group_label>Placebo-P + Metreleptin 5.0 mg</arm_group_label>
    <other_name>Placebo matched to pramlintide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo-M</intervention_name>
    <description>subcutaneous injection, twice a day</description>
    <arm_group_label>Placebo-P + Placebo-M</arm_group_label>
    <arm_group_label>Pramlintide 360 mcg + Placebo-M</arm_group_label>
    <other_name>Placebo matched to Metreleptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 65 years old.

          -  Is obese (Body Mass Index [BMI]&gt;=30kg/m^2 and &lt;=35kg/m^2); or overweight
             (BMI&gt;=27kg/m^2 and &lt;30kg/m^2.

          -  Has stable body weight, i.e., not varying by &gt;3% within 3 months prior to study.

          -  Has not been treated over the past 3 months or is currently treated with any of the
             following medications: Oral contraceptives (female subjects); Hormone replacement
             therapy (female subjects); Metformin for the treatment of polycystic ovary syndrome
             (female subjects); Antihypertensive agents; Lipid-lowering agents; Thyroid replacement
             therapy; selective serotonin reuptake inhibitors (SSRIs).

          -  Is comfortable with having repeated telephone contacts with a lifestyle counselor
             during the study.

          -  Is a nonsmoker (has not smoked for at least 6 months prior to the study).

        Exclusion Criteria:

          -  Has a medical history (e.g., morbid childhood obesity) and/or physical characteristics
             suggestive of genetic obesity or syndromatic obesity (e.g., Prader-Willi syndrome,
             Bardet-Biedl syndrome).

          -  Is currently enrolled or plans to enroll in a diet, weight loss, or exercise program
             with the specific intent of losing weight (subjects who have been following an
             exercise regimen resulting in stable weight maintenance for at least 2 months prior to
             enrollment are eligible for study inclusion)

          -  Has been treated over the past 2 months, is currently treated, or is expected to
             require or undergo treatment with *antiobesity agents (prescription or
             over-the-counter), *antipsychotic agents, *antiepileptic agents, *antidepressant
             agents, *drugs that directly affect gastrointestinal motility, *antidiabetic
             medications.

          -  Has previously received treatment with metreleptin or pramlintide in a clinical study
             or has received prior treatment with pramlintide (SYMLIN®).

          -  Has received any investigational drug within 30 days or within a period corresponding
             to 5 half-lives of that drug, whichever is greater, prior to this study starting.

          -  Has had a major surgery or a blood transfusion, or has donated blood over the past 2
             months or is planning to donate blood during the study.

          -  Has had liposuction, abdominoplasty, or similar procedure over the past year or is
             planning to have such a procedure during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vice President Research and Development, MD</last_name>
    <role>Study Director</role>
    <affiliation>Amylin Pharmaceuticals, LLC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pembrook Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belingham</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <results_first_submitted>August 12, 2013</results_first_submitted>
  <results_first_submitted_qc>November 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 14, 2013</results_first_posted>
  <disposition_first_submitted>August 13, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 29, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 5, 2011</disposition_first_posted>
  <last_update_submitted>March 26, 2015</last_update_submitted>
  <last_update_submitted_qc>March 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>overweight</keyword>
  <keyword>obesity</keyword>
  <keyword>pramlintide</keyword>
  <keyword>metreleptin</keyword>
  <keyword>Amylin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramlintide</mesh_term>
    <mesh_term>Islet Amyloid Polypeptide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First participant dosed/lead in: 06 May 2008; last participant's final visit: 07 April 2009. Study conducted in 42 clinics in participants who were either obese (body mass index (BMI) greater than, equal to (&gt;=) 30 kg/m^2 and less than equal to (&lt;=) 45 kg/m^2) or overweight (&gt;= 27 kg/m^2 and &lt; 30 kg/m^2).</recruitment_details>
      <pre_assignment_details>Participants enrolled, not randomized /treated (28): withdrew consent (10), adverse event (1), investigator decision (7), protocol violation (4), lost to follow up (5), administrative (1). 1 Week Lead-in Period: all arms received placebo matched to metreleptin and matched to pramlintide, BID (single blind); 28 week double blind Treatment Period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Self administered twice a day (BID) for 28 weeks, subcutaneous (SC) placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
        </group>
        <group group_id="P2">
          <title>Pramlintide 360 mcg</title>
          <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
        </group>
        <group group_id="P3">
          <title>Metreleptin 5.0 mg</title>
          <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
        </group>
        <group group_id="P4">
          <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
        </group>
        <group group_id="P5">
          <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
        </group>
        <group group_id="P6">
          <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
        </group>
        <group group_id="P7">
          <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
        </group>
        <group group_id="P8">
          <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="77"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="75"/>
                <participants group_id="P5" count="78"/>
                <participants group_id="P6" count="78"/>
                <participants group_id="P7" count="78"/>
                <participants group_id="P8" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="48"/>
                <participants group_id="P6" count="44"/>
                <participants group_id="P7" count="48"/>
                <participants group_id="P8" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="34"/>
                <participants group_id="P7" count="30"/>
                <participants group_id="P8" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="21"/>
                <participants group_id="P7" count="15"/>
                <participants group_id="P8" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat population. All participants randomized to a treatment and received at least 1 dose. Drug Randomization stratified:sex,3 categories baseline BMI (12 arms); 3 treatment arms combined for summaries as single placebo treatment group; 3 combined for summaries as single pramlintide monotherapy treatment group (total:8 treatment groups).</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
        </group>
        <group group_id="B2">
          <title>Pramlintide 360 mcg</title>
          <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
        </group>
        <group group_id="B3">
          <title>Metreleptin 5.0 mg</title>
          <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
        </group>
        <group group_id="B4">
          <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
        </group>
        <group group_id="B5">
          <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
        </group>
        <group group_id="B6">
          <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
        </group>
        <group group_id="B7">
          <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
        </group>
        <group group_id="B8">
          <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="77"/>
            <count group_id="B3" value="72"/>
            <count group_id="B4" value="75"/>
            <count group_id="B5" value="78"/>
            <count group_id="B6" value="78"/>
            <count group_id="B7" value="78"/>
            <count group_id="B8" value="75"/>
            <count group_id="B9" value="608"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.9" spread="11.35"/>
                    <measurement group_id="B2" value="42.0" spread="11.42"/>
                    <measurement group_id="B3" value="45.9" spread="10.92"/>
                    <measurement group_id="B4" value="45.8" spread="10.80"/>
                    <measurement group_id="B5" value="46.8" spread="10.54"/>
                    <measurement group_id="B6" value="44.4" spread="10.87"/>
                    <measurement group_id="B7" value="45.2" spread="10.07"/>
                    <measurement group_id="B8" value="44.7" spread="11.32"/>
                    <measurement group_id="B9" value="44.6" spread="10.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="54"/>
                    <measurement group_id="B6" value="54"/>
                    <measurement group_id="B7" value="55"/>
                    <measurement group_id="B8" value="52"/>
                    <measurement group_id="B9" value="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="23"/>
                    <measurement group_id="B9" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="78"/>
                    <measurement group_id="B6" value="78"/>
                    <measurement group_id="B7" value="78"/>
                    <measurement group_id="B8" value="75"/>
                    <measurement group_id="B9" value="608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>Body Mass Index (BMI)calculated using baseline weight and height; BMI = kg body weight/meters of height^2. Weight, height measured on Day 1. If Day 1 value missing or value obtained after the first dose, the last available value prior to Day 1 was used.</description>
          <units>(kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.88" spread="4.473"/>
                    <measurement group_id="B2" value="36.93" spread="4.389"/>
                    <measurement group_id="B3" value="36.62" spread="4.478"/>
                    <measurement group_id="B4" value="36.88" spread="4.336"/>
                    <measurement group_id="B5" value="36.65" spread="4.379"/>
                    <measurement group_id="B6" value="36.80" spread="4.260"/>
                    <measurement group_id="B7" value="36.96" spread="4.406"/>
                    <measurement group_id="B8" value="36.68" spread="4.504"/>
                    <measurement group_id="B9" value="36.80" spread="4.379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable Population</title>
        <description>Body weight was measured in kilogram (kg). Baseline is defined as Day 1. If Day 1 was missing or after the first dose date of randomized treatment, the last available value prior to Day 1 was used. Drug Randomization stratified by sex and 3 categories baseline BMI (12 arms); 3 treatment arms combined for summaries as single placebo treatment group; 3 combined for summaries as single pramlintide monotherapy treatment group (total: 8 treatment groups).</description>
        <time_frame>Baseline to Week 28</time_frame>
        <population>Evaluable population includes all intent to treat participants (received at least one dose of randomized treatment) who had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable Population</title>
          <description>Body weight was measured in kilogram (kg). Baseline is defined as Day 1. If Day 1 was missing or after the first dose date of randomized treatment, the last available value prior to Day 1 was used. Drug Randomization stratified by sex and 3 categories baseline BMI (12 arms); 3 treatment arms combined for summaries as single placebo treatment group; 3 combined for summaries as single pramlintide monotherapy treatment group (total: 8 treatment groups).</description>
          <population>Evaluable population includes all intent to treat participants (received at least one dose of randomized treatment) who had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding.</population>
          <units>Percentage change in kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" lower_limit="-3.76" upper_limit="-0.26"/>
                    <measurement group_id="O2" value="-5.47" lower_limit="-7.19" upper_limit="-3.76"/>
                    <measurement group_id="O3" value="-5.83" lower_limit="-7.72" upper_limit="-3.95"/>
                    <measurement group_id="O4" value="-6.85" lower_limit="-8.61" upper_limit="-5.08"/>
                    <measurement group_id="O5" value="-6.61" lower_limit="-8.41" upper_limit="-4.82"/>
                    <measurement group_id="O6" value="-6.39" lower_limit="-8.18" upper_limit="-4.59"/>
                    <measurement group_id="O7" value="-6.98" lower_limit="-8.79" upper_limit="-5.17"/>
                    <measurement group_id="O8" value="-7.02" lower_limit="-8.94" upper_limit="-5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>When multiplicity not considered, sample size of 50 participants per arm (after dropouts) was considered adequate to detect a difference of 4.5% in mean body weight change from baseline to Week 28 between one effective pramlintide + metreleptin combination treatment group versus the placebo, Pramlintide 360 mcg BID + Placebo-M, or Metreleptin 5.0 mg BID + Placebo-P treatment arms with approximately 90% power, assuming a common within-treatment standard deviation of 6.858%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>When multiplicity not considered, sample size of 50 participants per arm (after dropouts) was considered adequate to detect a difference of 4.5% in mean body weight change from baseline to Week 28 between one effective pramlintide + metreleptin combination treatment group versus the placebo, Pramlintide 360 mcg BID + Placebo-M, or Metreleptin 5.0 mg BID + Placebo-P treatment arms with approximately 90% power, assuming a common within-treatment standard deviation of 6.858%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>When multiplicity not considered, sample size of 50 participants per arm (after dropouts) was considered adequate to detect a difference of 4.5% in mean body weight change from baseline to Week 28 between one effective pramlintide + metreleptin combination treatment group versus the placebo, Pramlintide 360 mcg BID + Placebo-M, or Metreleptin 5.0 mg BID + Placebo-P treatment arms with approximately 90% power, assuming a common within-treatment standard deviation of 6.858%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>When multiplicity not considered, sample size of 50 participants per arm (after dropouts) was considered adequate to detect a difference of 4.5% in mean body weight change from baseline to Week 28 between one effective pramlintide + metreleptin combination treatment group versus the placebo, Pramlintide 360 mcg BID + Placebo-M, or Metreleptin 5.0 mg BID + Placebo-P treatment arms with approximately 90% power, assuming a common within-treatment standard deviation of 6.858%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2510</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>When multiplicity not considered, sample size of 50 participants per arm (after dropouts) was considered adequate to detect a difference of 4.5% in mean body weight change from baseline to Week 28 between one effective pramlintide + metreleptin combination treatment group versus the placebo, Pramlintide 360 mcg BID + Placebo-M, or Metreleptin 5.0 mg BID + Placebo-P treatment arms with approximately 90% power, assuming a common within-treatment standard deviation of 6.858%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3433</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>When multiplicity not considered, sample size of 50 participants per arm (after dropouts) was considered adequate to detect a difference of 4.5% in mean body weight change from baseline to Week 28 between one effective pramlintide + metreleptin combination treatment group versus the placebo, Pramlintide 360 mcg BID + Placebo-M, or Metreleptin 5.0 mg BID + Placebo-P treatment arms with approximately 90% power, assuming a common within-treatment standard deviation of 6.858%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4503</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>When multiplicity not considered, sample size of 50 participants per arm (after dropouts) was considered adequate to detect a difference of 4.5% in mean body weight change from baseline to Week 28 between one effective pramlintide + metreleptin combination treatment group versus the placebo, Pramlintide 360 mcg BID + Placebo-M, or Metreleptin 5.0 mg BID + Placebo-P treatment arms with approximately 90% power, assuming a common within-treatment standard deviation of 6.858%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2122</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>When multiplicity not considered, sample size of 50 participants per arm (after dropouts) was considered adequate to detect a difference of 4.5% in mean body weight change from baseline to Week 28 between one effective pramlintide + metreleptin combination treatment group versus the placebo, Pramlintide 360 mcg BID + Placebo-M, or Metreleptin 5.0 mg BID + Placebo-P treatment arms with approximately 90% power, assuming a common within-treatment standard deviation of 6.858%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2232</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>When multiplicity not considered, sample size of 50 participants per arm (after dropouts) was considered adequate to detect a difference of 4.5% in mean body weight change from baseline to Week 28 between one effective pramlintide + metreleptin combination treatment group versus the placebo, Pramlintide 360 mcg BID + Placebo-M, or Metreleptin 5.0 mg BID + Placebo-P treatment arms with approximately 90% power, assuming a common within-treatment standard deviation of 6.858%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4207</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>When multiplicity not considered, sample size of 50 participants per arm (after dropouts) was considered adequate to detect a difference of 4.5% in mean body weight change from baseline to Week 28 between one effective pramlintide + metreleptin combination treatment group versus the placebo, Pramlintide 360 mcg BID + Placebo-M, or Metreleptin 5.0 mg BID + Placebo-P treatment arms with approximately 90% power, assuming a common within-treatment standard deviation of 6.858%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5375</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>When multiplicity not considered, sample size of 50 participants per arm (after dropouts) was considered adequate to detect a difference of 4.5% in mean body weight change from baseline to Week 28 between one effective pramlintide + metreleptin combination treatment group versus the placebo, Pramlintide 360 mcg BID + Placebo-M, or Metreleptin 5.0 mg BID + Placebo-P treatment arms with approximately 90% power, assuming a common within-treatment standard deviation of 6.858%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6633</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>When multiplicity not considered, sample size of 50 participants per arm (after dropouts) was considered adequate to detect a difference of 4.5% in mean body weight change from baseline to Week 28 between one effective pramlintide + metreleptin combination treatment group versus the placebo, Pramlintide 360 mcg BID + Placebo-M, or Metreleptin 5.0 mg BID + Placebo-P treatment arms with approximately 90% power, assuming a common within-treatment standard deviation of 6.858%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3667</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>When multiplicity not considered, sample size of 50 participants per arm (after dropouts) was considered adequate to detect a difference of 4.5% in mean body weight change from baseline to Week 28 between one effective pramlintide + metreleptin combination treatment group versus the placebo, Pramlintide 360 mcg BID + Placebo-M, or Metreleptin 5.0 mg BID + Placebo-P treatment arms with approximately 90% power, assuming a common within-treatment standard deviation of 6.858%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3720</p_value>
            <p_value_desc>unadjusted for multiple comparisons; significance level of 0.0492 based on the Haybittle-Peto Criterion.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population</title>
        <description>Baseline refers to Day 1. If Day 1 value is missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 is used.</description>
        <time_frame>Baseline to Week 28</time_frame>
        <population>Evaluable population includes all intent to treat participants (received at least one dose of randomized treatment) who had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving at Least 5% and at Least 10% Body Weight Loss From Baseline to Week 28 - Evaluable Population</title>
          <description>Baseline refers to Day 1. If Day 1 value is missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 is used.</description>
          <population>Evaluable population includes all intent to treat participants (received at least one dose of randomized treatment) who had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight Loss &gt;=5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="29"/>
                    <measurement group_id="O8" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight Loss &gt;=5% and &lt;10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight Loss &gt;=10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight Gain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Weight Change or Weight Loss &lt;5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Change From Baseline to Weeks 4, 12, 28 in Mean Trough Concentration of Total Leptin - Evaluable Population</title>
        <description>Mean fasting plasma total leptin concentration (nanograms per milliliter; ng/mL) change from baseline over time by pooled metreleptin dose (sex, baseline BMI category, and baseline value). Baseline defined as Day 1. If Day 1 value is missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 is used. Evaluable population: all participants who received at least one dose of randomized treatment, had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding. Leptin concentrations measured using a validated immunoenzymetric assay utilizing polyclonal capture antibody, monoclonal detection antibody, and colorimetric readout by Amylin Pharmaceuticals, Inc.</description>
        <time_frame>Baseline to Week 28</time_frame>
        <population>Number analyzed (n) at baseline above. Week 4: n=41 45,46, 45, 45, 38; Week 8: n=41,45,46,44,45,37; Week 12: n=41, 46, 46, 45,45,38; Week 16: n=41,47,46,45,45,38; Week 20: n=41, 45,45,45,45,38; Week 24: n=40, 43, 46, 42, 44,38; Week 28: n=41, 45, 45, 44, 43, 36. Leptin concentration for placebo and pramlintide plus placebo groups not presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O3">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change From Baseline to Weeks 4, 12, 28 in Mean Trough Concentration of Total Leptin - Evaluable Population</title>
          <description>Mean fasting plasma total leptin concentration (nanograms per milliliter; ng/mL) change from baseline over time by pooled metreleptin dose (sex, baseline BMI category, and baseline value). Baseline defined as Day 1. If Day 1 value is missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 is used. Evaluable population: all participants who received at least one dose of randomized treatment, had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding. Leptin concentrations measured using a validated immunoenzymetric assay utilizing polyclonal capture antibody, monoclonal detection antibody, and colorimetric readout by Amylin Pharmaceuticals, Inc.</description>
          <population>Number analyzed (n) at baseline above. Week 4: n=41 45,46, 45, 45, 38; Week 8: n=41,45,46,44,45,37; Week 12: n=41, 46, 46, 45,45,38; Week 16: n=41,47,46,45,45,38; Week 20: n=41, 45,45,45,45,38; Week 24: n=40, 43, 46, 42, 44,38; Week 28: n=41, 45, 45, 44, 43, 36. Leptin concentration for placebo and pramlintide plus placebo groups not presented.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.26" spread="64.542"/>
                    <measurement group_id="O2" value="31.00" spread="73.953"/>
                    <measurement group_id="O3" value="47.82" spread="76.469"/>
                    <measurement group_id="O4" value="-2.36" spread="16.918"/>
                    <measurement group_id="O5" value="14.66" spread="48.212"/>
                    <measurement group_id="O6" value="49.16" spread="70.881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386.48" spread="408.472"/>
                    <measurement group_id="O2" value="167.62" spread="147.512"/>
                    <measurement group_id="O3" value="353.61" spread="265.727"/>
                    <measurement group_id="O4" value="53.76" spread="68.627"/>
                    <measurement group_id="O5" value="165.65" spread="173.851"/>
                    <measurement group_id="O6" value="399.74" spread="378.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="557.22" spread="604.617"/>
                    <measurement group_id="O2" value="373.64" spread="465.511"/>
                    <measurement group_id="O3" value="487.17" spread="625.071"/>
                    <measurement group_id="O4" value="105.96" spread="143.680"/>
                    <measurement group_id="O5" value="266.02" spread="210.412"/>
                    <measurement group_id="O6" value="393.06" spread="381.428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Absolute Change in Body Weight From Baseline to Weeks 4, 12, and 28 - Evaluable Population</title>
        <description>Least Squares (LS) mean absolute change in Body weight was measured in kilograms (kg). Baseline is defined as Day 1. If Day 1 was missing or after the first dose date of randomized treatment, the last available value prior to Day 1 was used.</description>
        <time_frame>Baseline to Week 28</time_frame>
        <population>Evaluable population includes all intent to treat participants (received at least one dose of randomized treatment) who had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Absolute Change in Body Weight From Baseline to Weeks 4, 12, and 28 - Evaluable Population</title>
          <description>Least Squares (LS) mean absolute change in Body weight was measured in kilograms (kg). Baseline is defined as Day 1. If Day 1 was missing or after the first dose date of randomized treatment, the last available value prior to Day 1 was used.</description>
          <population>Evaluable population includes all intent to treat participants (received at least one dose of randomized treatment) who had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" lower_limit="-2.38" upper_limit="-1.24"/>
                    <measurement group_id="O2" value="-2.85" lower_limit="-3.41" upper_limit="-2.29"/>
                    <measurement group_id="O3" value="-2.54" lower_limit="-3.15" upper_limit="-1.92"/>
                    <measurement group_id="O4" value="-2.94" lower_limit="-3.51" upper_limit="-2.36"/>
                    <measurement group_id="O5" value="-2.40" lower_limit="-2.99" upper_limit="-1.82"/>
                    <measurement group_id="O6" value="-2.62" lower_limit="-3.21" upper_limit="-2.04"/>
                    <measurement group_id="O7" value="-3.21" lower_limit="-3.80" upper_limit="-2.62"/>
                    <measurement group_id="O8" value="-3.32" lower_limit="-3.95" upper_limit="-2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.39" lower_limit="-4.50" upper_limit="-2.28"/>
                    <measurement group_id="O2" value="-4.90" lower_limit="-5.97" upper_limit="-3.83"/>
                    <measurement group_id="O3" value="-5.13" lower_limit="-6.31" upper_limit="-3.95"/>
                    <measurement group_id="O4" value="-5.52" lower_limit="-6.63" upper_limit="-4.42"/>
                    <measurement group_id="O5" value="-4.53" lower_limit="-5.65" upper_limit="-4.41"/>
                    <measurement group_id="O6" value="-5.52" lower_limit="-6.64" upper_limit="-4.40"/>
                    <measurement group_id="O7" value="-5.88" lower_limit="-7.02" upper_limit="-4.75"/>
                    <measurement group_id="O8" value="-6.12" lower_limit="-7.32" upper_limit="-4.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" lower_limit="-3.82" upper_limit="-0.26"/>
                    <measurement group_id="O2" value="-5.66" lower_limit="-7.40" upper_limit="-3.92"/>
                    <measurement group_id="O3" value="-6.18" lower_limit="-8.10" upper_limit="-4.27"/>
                    <measurement group_id="O4" value="-6.96" lower_limit="-8.75" upper_limit="-5.17"/>
                    <measurement group_id="O5" value="-6.55" lower_limit="-8.38" upper_limit="-4.72"/>
                    <measurement group_id="O6" value="-6.38" lower_limit="-8.20" upper_limit="-4.56"/>
                    <measurement group_id="O7" value="-7.18" lower_limit="-9.03" upper_limit="-5.34"/>
                    <measurement group_id="O8" value="-6.97" lower_limit="-8.92" upper_limit="-5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Change in Waist Circumference From Baseline to Week 12 and Week 28 - Evaluable Population</title>
        <description>Waist circumference was measured at baseline (Day 1), Weeks 12, 28 (or at early termination) in centimeters (cm).</description>
        <time_frame>Baseline to Weeks 12 and Week 28</time_frame>
        <population>Participants who received at least 1 dose of randomized treatment and who had adequate exposure to treatment and complied with the protocol as assessed prior to database lock/unblinding. Numbers (n) analyzed Week 12 n=45,51,41,47,45,45,45,38 in each treatment group respectively; Week 28 n= 44, 51, 41, 46, 45, 44, 43, 38 in each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Change in Waist Circumference From Baseline to Week 12 and Week 28 - Evaluable Population</title>
          <description>Waist circumference was measured at baseline (Day 1), Weeks 12, 28 (or at early termination) in centimeters (cm).</description>
          <population>Participants who received at least 1 dose of randomized treatment and who had adequate exposure to treatment and complied with the protocol as assessed prior to database lock/unblinding. Numbers (n) analyzed Week 12 n=45,51,41,47,45,45,45,38 in each treatment group respectively; Week 28 n= 44, 51, 41, 46, 45, 44, 43, 38 in each group, respectively.</population>
          <units>cm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.03" spread="0.851"/>
                    <measurement group_id="O2" value="-3.40" spread="0.799"/>
                    <measurement group_id="O3" value="-3.41" spread="0.895"/>
                    <measurement group_id="O4" value="-4.91" spread="0.846"/>
                    <measurement group_id="O5" value="-4.29" spread="0.876"/>
                    <measurement group_id="O6" value="-3.32" spread="0.853"/>
                    <measurement group_id="O7" value="-4.63" spread="0.855"/>
                    <measurement group_id="O8" value="-5.23" spread="0.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.54" spread="1.038"/>
                    <measurement group_id="O2" value="-3.95" spread="0.965"/>
                    <measurement group_id="O3" value="-3.86" spread="1.081"/>
                    <measurement group_id="O4" value="-5.48" spread="1.032"/>
                    <measurement group_id="O5" value="-5.75" spread="1.058"/>
                    <measurement group_id="O6" value="-4.70" spread="1.043"/>
                    <measurement group_id="O7" value="-5.52" spread="1.057"/>
                    <measurement group_id="O8" value="-6.53" spread="1.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change at Week 28 based on a general linear model with factors for treatment group, sex, baseline BMI category, and baseline value as a covariate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0404</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Change at Week 28 based on a general linear model with factors for treatment group, sex, baseline BMI category, and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0265</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Change at Week 28 based on a general linear model with factors for treatment group, sex, baseline BMI category, and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1357</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Change at Week 28 based on a general linear model with factors for treatment group, sex, baseline BMI category, and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0409</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Change at Week 28 based on a general linear model with factors for treatment group, sex, baseline BMI category, and baseline value as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0082</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean of the Total Area Under the Concentration Time Curve (AUC) From Time 0 to Last Quantifiable Concentration (Tlast) for Pramlintide at Weeks 4 and 24 - Evaluable Population Receiving Pramlintide</title>
        <description>Assessment of AUC was over a period of 2 hours following pramlintide administration. AUC (0 to time of last quantifiable concentration (-tlast). For AUC calculation, concentration at -5 min will be considered as 0 h concentration if quantifiable, otherwise, t=0 h. AUC measured as picograms*hour/milliliter (pg*h/mL). Pramlintide concentrations measured using a colorimetric immunoenzymetric assay employing monoclonal antibodies against pramlintide for both capture and detection.</description>
        <time_frame>Week 4 and Week 24</time_frame>
        <population>Evaluable population: participants received at least one dose of randomized treatment, had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding. Number (n) analyzed at Week 4:n=46, 40,41, 40,40,33 in each arm respectively;Week 24:n=48, 38, 44, 40, 35, 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Pramlintide 360 mcg + Placebo-M</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O3">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of the Total Area Under the Concentration Time Curve (AUC) From Time 0 to Last Quantifiable Concentration (Tlast) for Pramlintide at Weeks 4 and 24 - Evaluable Population Receiving Pramlintide</title>
          <description>Assessment of AUC was over a period of 2 hours following pramlintide administration. AUC (0 to time of last quantifiable concentration (-tlast). For AUC calculation, concentration at -5 min will be considered as 0 h concentration if quantifiable, otherwise, t=0 h. AUC measured as picograms*hour/milliliter (pg*h/mL). Pramlintide concentrations measured using a colorimetric immunoenzymetric assay employing monoclonal antibodies against pramlintide for both capture and detection.</description>
          <population>Evaluable population: participants received at least one dose of randomized treatment, had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding. Number (n) analyzed at Week 4:n=46, 40,41, 40,40,33 in each arm respectively;Week 24:n=48, 38, 44, 40, 35, 36.</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 AUC (0-tlast)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1862.5" spread="176.83"/>
                    <measurement group_id="O2" value="878.8" spread="87.34"/>
                    <measurement group_id="O3" value="967.5" spread="68.59"/>
                    <measurement group_id="O4" value="1788.2" spread="165.32"/>
                    <measurement group_id="O5" value="1920.1" spread="143.54"/>
                    <measurement group_id="O6" value="2060.4" spread="168.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 AUC (0-tlast)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1968.4" spread="135.60"/>
                    <measurement group_id="O2" value="1033.8" spread="102.19"/>
                    <measurement group_id="O3" value="953.7" spread="76.19"/>
                    <measurement group_id="O4" value="1536.3" spread="103.90"/>
                    <measurement group_id="O5" value="1990.2" spread="160.49"/>
                    <measurement group_id="O6" value="1915.3" spread="158.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean of AUC From Time 0 to Infinity for Pramlintide at Weeks 4 and 24 - Evaluable Population Treated With Pramlintide</title>
        <description>Assessment of AUC was over a period of 2 hours following pramlintide administration. Area under the concentration curve (AUC) time 0 to infinity (-inf). For AUC calculations, concentration at -5 min will be considered as 0 h concentration if quantifiable. AUC measured in picograms*hour/milliliter (pg*h/mL).</description>
        <time_frame>Weeks 4 and 24</time_frame>
        <population>Evaluable population: participants received at least one dose of randomized treatment, had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding. Number (n) analyzed at Week 4: n=39,36,37,36,35,31 in each arm, respectively; Week 24 n=46, 35, 42, 39, 33, 35 in each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Pramlintide 360 mcg + Placebo-M</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O3">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of AUC From Time 0 to Infinity for Pramlintide at Weeks 4 and 24 - Evaluable Population Treated With Pramlintide</title>
          <description>Assessment of AUC was over a period of 2 hours following pramlintide administration. Area under the concentration curve (AUC) time 0 to infinity (-inf). For AUC calculations, concentration at -5 min will be considered as 0 h concentration if quantifiable. AUC measured in picograms*hour/milliliter (pg*h/mL).</description>
          <population>Evaluable population: participants received at least one dose of randomized treatment, had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding. Number (n) analyzed at Week 4: n=39,36,37,36,35,31 in each arm, respectively; Week 24 n=46, 35, 42, 39, 33, 35 in each arm, respectively.</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 AUC (0-inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2662.7" spread="230.34"/>
                    <measurement group_id="O2" value="989.3" spread="96.05"/>
                    <measurement group_id="O3" value="1240.7" spread="106.08"/>
                    <measurement group_id="O4" value="2159.0" spread="238.45"/>
                    <measurement group_id="O5" value="2311.3" spread="211.63"/>
                    <measurement group_id="O6" value="2511.4" spread="241.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 AUC (0-inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2499.5" spread="215.51"/>
                    <measurement group_id="O2" value="1175.1" spread="116.89"/>
                    <measurement group_id="O3" value="1216.7" spread="102.07"/>
                    <measurement group_id="O4" value="1907.5" spread="153.91"/>
                    <measurement group_id="O5" value="2411.8" spread="218.29"/>
                    <measurement group_id="O6" value="2349.3" spread="210.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) for Pramlintide at Weeks 4 and 24 - Evaluable Population Receiving Pramlintide</title>
        <description>Assessment of Cmax was over a period of 2 hours following pramlintide administration at Weeks 4 and 24. Cmax was measured as picograms/milliliter (pg/mL).</description>
        <time_frame>Week 4 and Week 24</time_frame>
        <population>Evaluable population: participants received at least one dose of randomized treatment, had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding. Number (n) analyzed at Week 4 n=46,40,41,40,40,33 in each arm, respectively; Week 24 n=48,38, 44,40,35,36 in each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Pramlintide 360 mcg + Placebo-M</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O3">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean of the Maximum Observed Plasma Concentration (Cmax) for Pramlintide at Weeks 4 and 24 - Evaluable Population Receiving Pramlintide</title>
          <description>Assessment of Cmax was over a period of 2 hours following pramlintide administration at Weeks 4 and 24. Cmax was measured as picograms/milliliter (pg/mL).</description>
          <population>Evaluable population: participants received at least one dose of randomized treatment, had adequate exposure to treatment and complied with the protocol as assessed prior to database lock and unblinding. Number (n) analyzed at Week 4 n=46,40,41,40,40,33 in each arm, respectively; Week 24 n=48,38, 44,40,35,36 in each arm, respectively.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1759.0" spread="168.40"/>
                    <measurement group_id="O2" value="876.7" spread="77.37"/>
                    <measurement group_id="O3" value="897.3" spread="51.16"/>
                    <measurement group_id="O4" value="1783.8" spread="144.34"/>
                    <measurement group_id="O5" value="1851.3" spread="118.87"/>
                    <measurement group_id="O6" value="2096.4" spread="149.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1985.8" spread="118.31"/>
                    <measurement group_id="O2" value="1048.1" spread="76.86"/>
                    <measurement group_id="O3" value="925.5" spread="64.16"/>
                    <measurement group_id="O4" value="1573.5" spread="100.69"/>
                    <measurement group_id="O5" value="2032.0" spread="152.70"/>
                    <measurement group_id="O6" value="1972.2" spread="159.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares (LS) Mean Absolute Change From Baseline to Week 28 in Percent of Body Fat - Evaluable Population</title>
        <description>Parameters of body composition were measured with a Dual Energy X-ray absorptiometry (DEXA) scan and reported as a percent (%). Data from the first valid DEXA scan obtained no later than 7 days after the first randomized dose was considered as valid baseline values; data from the last valid DEXA scan obtained no later than 10 days after last clinical visit or no later than 14 days after last dose of randomized study medication was considered as valid study termination values. Absolute change from baseline was defined as percent body fat at Week 28 - percent body fat at baseline.</description>
        <time_frame>Baseline to Week 28</time_frame>
        <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Number analyzed (n) were of evaluable participants with valid DEXA scan at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares (LS) Mean Absolute Change From Baseline to Week 28 in Percent of Body Fat - Evaluable Population</title>
          <description>Parameters of body composition were measured with a Dual Energy X-ray absorptiometry (DEXA) scan and reported as a percent (%). Data from the first valid DEXA scan obtained no later than 7 days after the first randomized dose was considered as valid baseline values; data from the last valid DEXA scan obtained no later than 10 days after last clinical visit or no later than 14 days after last dose of randomized study medication was considered as valid study termination values. Absolute change from baseline was defined as percent body fat at Week 28 - percent body fat at baseline.</description>
          <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Number analyzed (n) were of evaluable participants with valid DEXA scan at Week 28.</population>
          <units>percentage of body fat</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="0.501"/>
                    <measurement group_id="O2" value="-1.77" spread="0.421"/>
                    <measurement group_id="O3" value="-1.94" spread="0.492"/>
                    <measurement group_id="O4" value="-2.32" spread="0.480"/>
                    <measurement group_id="O5" value="-2.21" spread="0.475"/>
                    <measurement group_id="O6" value="-2.21" spread="0.497"/>
                    <measurement group_id="O7" value="-1.56" spread="0.482"/>
                    <measurement group_id="O8" value="-2.46" spread="0.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0464</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0647</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0690</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3717</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0327</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Absolute Change From Baseline to Week 28 in Total Body Fat Mass (k) - Evaluable Population</title>
        <description>Parameters of body composition were measured with a Dual Energy X-ray absorptiometry (DEXA) scan. Data from the first valid DEXA scan obtained no later than 7 days after the first randomized dose was considered as valid baseline values; data from the last valid DEXA scan obtained no later than 10 days after last clinical visit or no later than 14 days after last dose of randomized study medication was considered as valid study termination values. Body fat mass was measured in kilogram (k).</description>
        <time_frame>Baseline to Week 28</time_frame>
        <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Number analyzed (n) were of evaluable participants with valid DEXA scan at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Absolute Change From Baseline to Week 28 in Total Body Fat Mass (k) - Evaluable Population</title>
          <description>Parameters of body composition were measured with a Dual Energy X-ray absorptiometry (DEXA) scan. Data from the first valid DEXA scan obtained no later than 7 days after the first randomized dose was considered as valid baseline values; data from the last valid DEXA scan obtained no later than 10 days after last clinical visit or no later than 14 days after last dose of randomized study medication was considered as valid study termination values. Body fat mass was measured in kilogram (k).</description>
          <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Number analyzed (n) were of evaluable participants with valid DEXA scan at Week 28.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="0.0779"/>
                    <measurement group_id="O2" value="-4.28" spread="0.661"/>
                    <measurement group_id="O3" value="-4.57" spread="0.763"/>
                    <measurement group_id="O4" value="-4.98" spread="0.746"/>
                    <measurement group_id="O5" value="-4.97" spread="0.734"/>
                    <measurement group_id="O6" value="-5.03" spread="0.755"/>
                    <measurement group_id="O7" value="-4.35" spread="0.748"/>
                    <measurement group_id="O8" value="-5.51" spread="0.792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0049</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0047</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0046</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0257</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Absolute Change From Baseline to Week 28 in Fat-free Mass (kg) - Evaluable Population</title>
        <description>Parameters of body composition were measured with a Dual Energy X-ray Absorptiometry (DEXA) scan. Data from the first valid DEXA scan obtained no later than 7 days after the first randomized dose was considered as valid baseline values; data from the last valid DEXA scan obtained no later than 10 days after last clinical visit or no later than 14 days after last dose of randomized study medication was considered as valid study termination values. Fat-free mass were measured in kilogram (k).</description>
        <time_frame>Baseline to Week 28</time_frame>
        <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Number analyzed (n) were of evaluable participants with valid DEXA scan at Week 28.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Absolute Change From Baseline to Week 28 in Fat-free Mass (kg) - Evaluable Population</title>
          <description>Parameters of body composition were measured with a Dual Energy X-ray Absorptiometry (DEXA) scan. Data from the first valid DEXA scan obtained no later than 7 days after the first randomized dose was considered as valid baseline values; data from the last valid DEXA scan obtained no later than 10 days after last clinical visit or no later than 14 days after last dose of randomized study medication was considered as valid study termination values. Fat-free mass were measured in kilogram (k).</description>
          <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Number analyzed (n) were of evaluable participants with valid DEXA scan at Week 28.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.393"/>
                    <measurement group_id="O2" value="-1.62" spread="0.337"/>
                    <measurement group_id="O3" value="-1.80" spread="0.389"/>
                    <measurement group_id="O4" value="-1.90" spread="0.377"/>
                    <measurement group_id="O5" value="-1.99" spread="0.373"/>
                    <measurement group_id="O6" value="-2.02" spread="0.391"/>
                    <measurement group_id="O7" value="-2.11" spread="0.380"/>
                    <measurement group_id="O8" value="-2.29" spread="0.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0222</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0128</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0122</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0073</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Based on a general linear model general linear model that includes baseline value and factors for treatment group, sex, baseline BMI category (&lt;35 kg/m2, 35 to &lt;40 kg/m2, ≥40 kg/m2).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LS Mean Absolute Change From Baseline to Week 28 in Fasting Plasma Glucose, Total Cholesterol (TC), Triglycerides, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol - Evaluable Population</title>
        <description>Baseline refers to Visit 5 (Day 1). If Day 1 value is missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 is used. Fasting samples were obtained at baseline, Weeks 4, 12, and 28. All parameters were measured in milligrams per deciliter (mg/dL).</description>
        <time_frame>Baseline to Week 28</time_frame>
        <population>Evaluable population: received at least one dose of randomized treatment, had adequate exposure to treatment, complied with the protocol as assessed prior to database lock and unblinding. Number analyzed (n) presented above for TC, LDL and HDL cholesterol. Glucose n= 43, 50, 41, 46, 45, 43,44,36; Triglycerides n= 44,50,41,46,45,44,44.38.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>LS Mean Absolute Change From Baseline to Week 28 in Fasting Plasma Glucose, Total Cholesterol (TC), Triglycerides, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol - Evaluable Population</title>
          <description>Baseline refers to Visit 5 (Day 1). If Day 1 value is missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 is used. Fasting samples were obtained at baseline, Weeks 4, 12, and 28. All parameters were measured in milligrams per deciliter (mg/dL).</description>
          <population>Evaluable population: received at least one dose of randomized treatment, had adequate exposure to treatment, complied with the protocol as assessed prior to database lock and unblinding. Number analyzed (n) presented above for TC, LDL and HDL cholesterol. Glucose n= 43, 50, 41, 46, 45, 43,44,36; Triglycerides n= 44,50,41,46,45,44,44.38.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="46"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="44"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fasting Plasma Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.35"/>
                    <measurement group_id="O2" value="-1.8" spread="1.25"/>
                    <measurement group_id="O3" value="-1.8" spread="1.39"/>
                    <measurement group_id="O4" value="-2.5" spread="1.32"/>
                    <measurement group_id="O5" value="-1.2" spread="1.34"/>
                    <measurement group_id="O6" value="-1.0" spread="1.36"/>
                    <measurement group_id="O7" value="-1.7" spread="1.35"/>
                    <measurement group_id="O8" value="-1.3" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="3.57"/>
                    <measurement group_id="O2" value="-7.1" spread="3.35"/>
                    <measurement group_id="O3" value="-3.7" spread="3.82"/>
                    <measurement group_id="O4" value="-2.1" spread="3.54"/>
                    <measurement group_id="O5" value="-2.5" spread="3.60"/>
                    <measurement group_id="O6" value="-0.6" spread="3.60"/>
                    <measurement group_id="O7" value="-4.0" spread="3.61"/>
                    <measurement group_id="O8" value="-1.3" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="8.25"/>
                    <measurement group_id="O2" value="-8.6" spread="7.73"/>
                    <measurement group_id="O3" value="-13.0" spread="8.66"/>
                    <measurement group_id="O4" value="-1.4" spread="8.17"/>
                    <measurement group_id="O5" value="-10.9" spread="8.29"/>
                    <measurement group_id="O6" value="11.1" spread="8.34"/>
                    <measurement group_id="O7" value="-9.2" spread="8.35"/>
                    <measurement group_id="O8" value="0.9" spread="8.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.82"/>
                    <measurement group_id="O2" value="-3.5" spread="2.65"/>
                    <measurement group_id="O3" value="-2.3" spread="3.02"/>
                    <measurement group_id="O4" value="-3.7" spread="2.80"/>
                    <measurement group_id="O5" value="-0.0" spread="2.85"/>
                    <measurement group_id="O6" value="-2.7" spread="2.85"/>
                    <measurement group_id="O7" value="-3.7" spread="2.86"/>
                    <measurement group_id="O8" value="-1.2" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.96"/>
                    <measurement group_id="O2" value="0.6" spread="0.90"/>
                    <measurement group_id="O3" value="2.6" spread="1.03"/>
                    <measurement group_id="O4" value="0.7" spread="0.95"/>
                    <measurement group_id="O5" value="1.0" spread="0.96"/>
                    <measurement group_id="O6" value="2.9" spread="0.97"/>
                    <measurement group_id="O7" value="0.97" spread="0.97"/>
                    <measurement group_id="O8" value="1.05" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Change From Baseline to Week 28 for Insulin - Evaluable Population</title>
        <description>Baseline refers to Visit 5 (Day 1). If Day 1 value is missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 is used. Fasting samples were obtained at baseline, Weeks 4, 12, and 28. Parameter was measured micro international units per milliliter. (µIU/mL).</description>
        <time_frame>Baseline to Week 28</time_frame>
        <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change From Baseline to Week 28 for Insulin - Evaluable Population</title>
          <description>Baseline refers to Visit 5 (Day 1). If Day 1 value is missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 is used. Fasting samples were obtained at baseline, Weeks 4, 12, and 28. Parameter was measured micro international units per milliliter. (µIU/mL).</description>
          <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding.</population>
          <units>µIU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="43"/>
                <count group_id="O8" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.01"/>
                    <measurement group_id="O2" value="-0.4" spread="0.94"/>
                    <measurement group_id="O3" value="-1.6" spread="1.0"/>
                    <measurement group_id="O4" value="-1.0" spread="1.00"/>
                    <measurement group_id="O5" value="-2.5" spread="0.99"/>
                    <measurement group_id="O6" value="-1.4" spread="1.00"/>
                    <measurement group_id="O7" value="-0.8" spread="1.01"/>
                    <measurement group_id="O8" value="-0.5" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Change From Screening to Week 24 in Impact of Weight on Quality of Life Questionnaire-lite Version (IWQOL-Lite) Total Score - Evaluable Population</title>
        <description>Subjective effects of weight loss were measured using the IWQOL-Lite questionnaire, a 31-item patient reported outcome (PRO) instrument used to assess the effect of weight on physical function, self-esteem, sexual life, public distress, and work. Individual items have a range of 1 to 5 with 5=always true and 1= never true. The total score for the IWQOL-Lite instrument is measured on a scale from 0 (worst) to 100 (best). Higher scores indicate improvement. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
        <time_frame>Screening to Week 24</time_frame>
        <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Missing item responses may be imputed for each subject as appropriate before summarization.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change From Screening to Week 24 in Impact of Weight on Quality of Life Questionnaire-lite Version (IWQOL-Lite) Total Score - Evaluable Population</title>
          <description>Subjective effects of weight loss were measured using the IWQOL-Lite questionnaire, a 31-item patient reported outcome (PRO) instrument used to assess the effect of weight on physical function, self-esteem, sexual life, public distress, and work. Individual items have a range of 1 to 5 with 5=always true and 1= never true. The total score for the IWQOL-Lite instrument is measured on a scale from 0 (worst) to 100 (best). Higher scores indicate improvement. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
          <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Missing item responses may be imputed for each subject as appropriate before summarization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="44"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.52" spread="12.480"/>
                    <measurement group_id="O2" value="10.31" spread="11.629"/>
                    <measurement group_id="O3" value="11.09" spread="13.503"/>
                    <measurement group_id="O4" value="10.14" spread="10.957"/>
                    <measurement group_id="O5" value="16.15" spread="15.193"/>
                    <measurement group_id="O6" value="13.84" spread="11.535"/>
                    <measurement group_id="O7" value="13.44" spread="11.175"/>
                    <measurement group_id="O8" value="11.68" spread="10.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Change From Screening to Week 24 in Binge Eating Scale (BES) Total Score - Evaluable Population</title>
        <description>The Binge Eating Scale (BES) is a 16-item questionnaire that assesses the behavioral and cognitive correlates of binge eating, including participants’ perceived self-control over eating behavior using a range of 1 to 4 with 1=positive perceptions and 4= negative perceptions. The minimum and maximum score for the BES instrument is 0 and 55, respectively. The higher the score the worse the outcome. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
        <time_frame>Screening to Week 24</time_frame>
        <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Missing item responses may be imputed for each subject as appropriate before summarization.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change From Screening to Week 24 in Binge Eating Scale (BES) Total Score - Evaluable Population</title>
          <description>The Binge Eating Scale (BES) is a 16-item questionnaire that assesses the behavioral and cognitive correlates of binge eating, including participants’ perceived self-control over eating behavior using a range of 1 to 4 with 1=positive perceptions and 4= negative perceptions. The minimum and maximum score for the BES instrument is 0 and 55, respectively. The higher the score the worse the outcome. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
          <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Missing item responses may be imputed for each subject as appropriate before summarization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="6.31"/>
                    <measurement group_id="O2" value="-3.4" spread="6.96"/>
                    <measurement group_id="O3" value="-4.0" spread="6.21"/>
                    <measurement group_id="O4" value="-4.4" spread="6.45"/>
                    <measurement group_id="O5" value="-6.6" spread="8.28"/>
                    <measurement group_id="O6" value="-3.5" spread="5.87"/>
                    <measurement group_id="O7" value="-5.9" spread="7.44"/>
                    <measurement group_id="O8" value="-5.2" spread="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Change From Screening to Week 24 in Susceptibility to Eating Questionnaire (SEQ) Item Scores - Evaluable Population</title>
        <description>The eating questionnaire is an exploratory measure of appetite, satiety, and perceived control over portion size using 10 VAS items with each response measured on a 100 mm visual analogue scale (ranges vary from Never to Very Often; Not at All Difficult to Extremely Difficult; Not at all Strong to Very Strong). Lower scores indicate improvement. The Eating Questionnaire instructed participants to rate their responses to these items over the past 7 days. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
        <time_frame>Screening to Week 24</time_frame>
        <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Missing item responses may be imputed for each subject as appropriate before summarization.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change From Screening to Week 24 in Susceptibility to Eating Questionnaire (SEQ) Item Scores - Evaluable Population</title>
          <description>The eating questionnaire is an exploratory measure of appetite, satiety, and perceived control over portion size using 10 VAS items with each response measured on a 100 mm visual analogue scale (ranges vary from Never to Very Often; Not at All Difficult to Extremely Difficult; Not at all Strong to Very Strong). Lower scores indicate improvement. The Eating Questionnaire instructed participants to rate their responses to these items over the past 7 days. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
          <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Missing item responses may be imputed for each subject as appropriate before summarization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="44"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Frequency of Food Cravings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="25.85"/>
                    <measurement group_id="O2" value="-6.6" spread="27.17"/>
                    <measurement group_id="O3" value="-4.0" spread="24.28"/>
                    <measurement group_id="O4" value="-14.1" spread="24.55"/>
                    <measurement group_id="O5" value="-19.8" spread="31.06"/>
                    <measurement group_id="O6" value="-15.7" spread="21.76"/>
                    <measurement group_id="O7" value="-18.5" spread="27.69"/>
                    <measurement group_id="O8" value="-13.5" spread="29.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strength of Food Cravings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="27.60"/>
                    <measurement group_id="O2" value="-6.1" spread="26.86"/>
                    <measurement group_id="O3" value="-1.1" spread="24.97"/>
                    <measurement group_id="O4" value="-13.9" spread="25.45"/>
                    <measurement group_id="O5" value="-13.8" spread="28.02"/>
                    <measurement group_id="O6" value="-12.9" spread="19.19"/>
                    <measurement group_id="O7" value="-19.6" spread="25.66"/>
                    <measurement group_id="O8" value="-15.2" spread="32.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficult to Control Eating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="27.45"/>
                    <measurement group_id="O2" value="-15.2" spread="26.37"/>
                    <measurement group_id="O3" value="-9.5" spread="27.44"/>
                    <measurement group_id="O4" value="-19.7" spread="23.00"/>
                    <measurement group_id="O5" value="-27.3" spread="27.02"/>
                    <measurement group_id="O6" value="-18.3" spread="19.46"/>
                    <measurement group_id="O7" value="-26.3" spread="28.89"/>
                    <measurement group_id="O8" value="-18.0" spread="35.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficult to Resist Food Cravings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.4" spread="30.32"/>
                    <measurement group_id="O2" value="-11.1" spread="24.52"/>
                    <measurement group_id="O3" value="9.6" spread="25.02"/>
                    <measurement group_id="O4" value="-19.5" spread="26.28"/>
                    <measurement group_id="O5" value="-21.8" spread="28.65"/>
                    <measurement group_id="O6" value="-19.0" spread="26.49"/>
                    <measurement group_id="O7" value="-28.0" spread="29.90"/>
                    <measurement group_id="O8" value="-18.2" spread="29.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eating in Response to Food Cravings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" spread="28.41"/>
                    <measurement group_id="O2" value="-12.2" spread="25.14"/>
                    <measurement group_id="O3" value="-12.6" spread="27.34"/>
                    <measurement group_id="O4" value="-15.4" spread="22.17"/>
                    <measurement group_id="O5" value="-22.2" spread="32.94"/>
                    <measurement group_id="O6" value="-18.5" spread="24.95"/>
                    <measurement group_id="O7" value="-22.9" spread="27.85"/>
                    <measurement group_id="O8" value="-15.9" spread="27.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficult to Control Portion Sizes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="23.37"/>
                    <measurement group_id="O2" value="-16.9" spread="29.58"/>
                    <measurement group_id="O3" value="-27.6" spread="30.70"/>
                    <measurement group_id="O4" value="-19.6" spread="21.19"/>
                    <measurement group_id="O5" value="-25.2" spread="28.00"/>
                    <measurement group_id="O6" value="-20.8" spread="21.18"/>
                    <measurement group_id="O7" value="-24.0" spread="26.91"/>
                    <measurement group_id="O8" value="-27.6" spread="34.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How Hungry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="20.59"/>
                    <measurement group_id="O2" value="-9.7" spread="22.92"/>
                    <measurement group_id="O3" value="-17.5" spread="23.18"/>
                    <measurement group_id="O4" value="-16.4" spread="24.00"/>
                    <measurement group_id="O5" value="-17.0" spread="24.09"/>
                    <measurement group_id="O6" value="-17.5" spread="22.53"/>
                    <measurement group_id="O7" value="-19.2" spread="24.64"/>
                    <measurement group_id="O8" value="-19.9" spread="31.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How Full After Meals</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="25.37"/>
                    <measurement group_id="O2" value="0.5" spread="25.05"/>
                    <measurement group_id="O3" value="-7.6" spread="19.94"/>
                    <measurement group_id="O4" value="-3.8" spread="26.19"/>
                    <measurement group_id="O5" value="-8.8" spread="31.83"/>
                    <measurement group_id="O6" value="-6.5" spread="26.46"/>
                    <measurement group_id="O7" value="-4.2" spread="27.71"/>
                    <measurement group_id="O8" value="1.1" spread="23.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoughts of Food</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="21.70"/>
                    <measurement group_id="O2" value="-10.7" spread="25.84"/>
                    <measurement group_id="O3" value="-10.6" spread="30.04"/>
                    <measurement group_id="O4" value="-9.4" spread="22.33"/>
                    <measurement group_id="O5" value="-16.7" spread="27.75"/>
                    <measurement group_id="O6" value="-12.0" spread="20.98"/>
                    <measurement group_id="O7" value="-20.0" spread="27.90"/>
                    <measurement group_id="O8" value="-5.6" spread="30.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How Pleasant Meals</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="19.72"/>
                    <measurement group_id="O2" value="-2.3" spread="24.55"/>
                    <measurement group_id="O3" value="-2.1" spread="21.00"/>
                    <measurement group_id="O4" value="1.2" spread="27.11"/>
                    <measurement group_id="O5" value="-1.2" spread="25.96"/>
                    <measurement group_id="O6" value="3.7" spread="24.87"/>
                    <measurement group_id="O7" value="5.3" spread="22.41"/>
                    <measurement group_id="O8" value="-2.1" spread="28.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Change From Screening to Week 24 in Hospital Anxiety and Depression Scale (HADS) Total Scores - Evaluable Population</title>
        <description>The HADS is a questionnaire that uses 14 items to assess both anxiety and depression over the past week. The odd numbered items constitute the anxiety subscale, and the even numbered items constitute the depression subscale. The individual response scores for each subscale component are added together to obtain the individual subscale scores. The minimum and maximum score for each subscale is 0 and 21, respectively. The higher the score, the worse the outcome. Values were obtained for this questionnaire on Visit 3 in the screening period</description>
        <time_frame>Screening to Week 24</time_frame>
        <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Missing item responses may be imputed for each subject as appropriate before summarization.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change From Screening to Week 24 in Hospital Anxiety and Depression Scale (HADS) Total Scores - Evaluable Population</title>
          <description>The HADS is a questionnaire that uses 14 items to assess both anxiety and depression over the past week. The odd numbered items constitute the anxiety subscale, and the even numbered items constitute the depression subscale. The individual response scores for each subscale component are added together to obtain the individual subscale scores. The minimum and maximum score for each subscale is 0 and 21, respectively. The higher the score, the worse the outcome. Values were obtained for this questionnaire on Visit 3 in the screening period</description>
          <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Missing item responses may be imputed for each subject as appropriate before summarization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="44"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety Total Scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.475"/>
                    <measurement group_id="O2" value="0.08" spread="0.274"/>
                    <measurement group_id="O3" value="-0.56" spread="0.342"/>
                    <measurement group_id="O4" value="-0.11" spread="0.431"/>
                    <measurement group_id="O5" value="-0.43" spread="0.373"/>
                    <measurement group_id="O6" value="-0.59" spread="0.370"/>
                    <measurement group_id="O7" value="-0.58" spread="0.429"/>
                    <measurement group_id="O8" value="0.06" spread="0.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression Total Scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="0.435"/>
                    <measurement group_id="O2" value="-0.76" spread="0.357"/>
                    <measurement group_id="O3" value="-0.98" spread="0.394"/>
                    <measurement group_id="O4" value="-0.66" spread="0.332"/>
                    <measurement group_id="O5" value="-1.37" spread="0.387"/>
                    <measurement group_id="O6" value="-1.23" spread="0.416"/>
                    <measurement group_id="O7" value="-1.02" spread="0.294"/>
                    <measurement group_id="O8" value="0.00" spread="0.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Change From Screening to Week 24 in Summary Scores for Profile of Mood States - Brief (POMS-B) - Evaluable Population</title>
        <description>The POMS is a mood scale consisting of 65 mood adjectives that assess participants’ mood over the past seven days. The POMS-B is an authorized, 30-item brief version of the POMS consisting of five items for each of the six POMS factors. The mood adjectives load onto 6 mood factors, which are as follows: Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment. Scores range from 0= Not at All to 4=Extremely. The factor scores are added to obtain the total mood disturbance score. A lower total mood disturbance score indicates improvement. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
        <time_frame>Screening to Week 24</time_frame>
        <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Missing item responses may be imputed for each subject as appropriate before summarization.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change From Screening to Week 24 in Summary Scores for Profile of Mood States - Brief (POMS-B) - Evaluable Population</title>
          <description>The POMS is a mood scale consisting of 65 mood adjectives that assess participants’ mood over the past seven days. The POMS-B is an authorized, 30-item brief version of the POMS consisting of five items for each of the six POMS factors. The mood adjectives load onto 6 mood factors, which are as follows: Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment. Scores range from 0= Not at All to 4=Extremely. The factor scores are added to obtain the total mood disturbance score. A lower total mood disturbance score indicates improvement. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
          <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Missing item responses may be imputed for each subject as appropriate before summarization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="43"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tension - Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.518"/>
                    <measurement group_id="O2" value="0.39" spread="0.308"/>
                    <measurement group_id="O3" value="-0.17" spread="0.389"/>
                    <measurement group_id="O4" value="0.87" spread="0.518"/>
                    <measurement group_id="O5" value="-0.30" spread="0.408"/>
                    <measurement group_id="O6" value="-0.21" spread="0.358"/>
                    <measurement group_id="O7" value="0.00" spread="0.423"/>
                    <measurement group_id="O8" value="0.66" spread="0.583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression - Dejection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.628"/>
                    <measurement group_id="O2" value="0.27" spread="0.489"/>
                    <measurement group_id="O3" value="0.44" spread="0.466"/>
                    <measurement group_id="O4" value="0.64" spread="0.410"/>
                    <measurement group_id="O5" value="0.26" spread="0.464"/>
                    <measurement group_id="O6" value="0.37" spread="0.381"/>
                    <measurement group_id="O7" value="-0.29" spread="0.348"/>
                    <measurement group_id="O8" value="0.23" spread="0.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anger - Hostility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.577"/>
                    <measurement group_id="O2" value="0.16" spread="0.418"/>
                    <measurement group_id="O3" value="-0.22" spread="0.468"/>
                    <measurement group_id="O4" value="0.53" spread="0.489"/>
                    <measurement group_id="O5" value="-0.30" spread="0.409"/>
                    <measurement group_id="O6" value="-0.05" spread="0.410"/>
                    <measurement group_id="O7" value="-0.18" spread="0.476"/>
                    <measurement group_id="O8" value="0.71" spread="0.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vigor - Activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="0.534"/>
                    <measurement group_id="O2" value="0.27" spread="0.681"/>
                    <measurement group_id="O3" value="0.78" spread="0.670"/>
                    <measurement group_id="O4" value="1.04" spread="0.603"/>
                    <measurement group_id="O5" value="1.20" spread="0.632"/>
                    <measurement group_id="O6" value="0.95" spread="0.773"/>
                    <measurement group_id="O7" value="1.13" spread="0.641"/>
                    <measurement group_id="O8" value="1.29" spread="0.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue - Inertia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="0.852"/>
                    <measurement group_id="O2" value="-0.53" spread="0.709"/>
                    <measurement group_id="O3" value="-1.10" spread="0.688"/>
                    <measurement group_id="O4" value="0.02" spread="0.660"/>
                    <measurement group_id="O5" value="-0.30" spread="0.676"/>
                    <measurement group_id="O6" value="-1.49" spread="0.626"/>
                    <measurement group_id="O7" value="-0.82" spread="0.667"/>
                    <measurement group_id="O8" value="0.09" spread="0.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confusion - Bewilderment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.471"/>
                    <measurement group_id="O2" value="0.51" spread="0.334"/>
                    <measurement group_id="O3" value="0.17" spread="0.296"/>
                    <measurement group_id="O4" value="0.40" spread="0.387"/>
                    <measurement group_id="O5" value="0.20" spread="0.400"/>
                    <measurement group_id="O6" value="0.05" spread="0.286"/>
                    <measurement group_id="O7" value="0.02" spread="0.280"/>
                    <measurement group_id="O8" value="0.00" spread="0.393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Change From Screening to Week 24 in Minutes to Fall Asleep, Hours of Sleep and The Pittsburgh Sleep Quality Index (PSQI) Global Score - Evaluable Population</title>
        <description>The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire which assesses sleep quality and sleep disturbances over a period of 1 month. The PSQI provides ratings on seven domains of sleep (subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction). The sum of the individual domains yields a global sleep quality score with a range of 0-21. A PSQI score &gt;5 is indicative of poor sleep, which is characterized by severe difficulties in at least two domains, or moderate difficulties in three or more domains. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
        <time_frame>Screening to Week 24</time_frame>
        <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Missing item responses may be imputed for each subject as appropriate before summarization.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change From Screening to Week 24 in Minutes to Fall Asleep, Hours of Sleep and The Pittsburgh Sleep Quality Index (PSQI) Global Score - Evaluable Population</title>
          <description>The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire which assesses sleep quality and sleep disturbances over a period of 1 month. The PSQI provides ratings on seven domains of sleep (subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction). The sum of the individual domains yields a global sleep quality score with a range of 0-21. A PSQI score &gt;5 is indicative of poor sleep, which is characterized by severe difficulties in at least two domains, or moderate difficulties in three or more domains. Values were obtained for this questionnaire on Visit 3 in the screening period.</description>
          <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Missing item responses may be imputed for each subject as appropriate before summarization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Minutes to Fall Asleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="11.17"/>
                    <measurement group_id="O2" value="1.3" spread="17.83"/>
                    <measurement group_id="O3" value="-2.1" spread="14.81"/>
                    <measurement group_id="O4" value="-4.3" spread="15.09"/>
                    <measurement group_id="O5" value="-4.6" spread="12.00"/>
                    <measurement group_id="O6" value="-4.3" spread="19.50"/>
                    <measurement group_id="O7" value="-1.0" spread="14.74"/>
                    <measurement group_id="O8" value="2.7" spread="16.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hours Asleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.80"/>
                    <measurement group_id="O2" value="0.1" spread="0.91"/>
                    <measurement group_id="O3" value="-0.1" spread="0.76"/>
                    <measurement group_id="O4" value="0.2" spread="1.09"/>
                    <measurement group_id="O5" value="0.1" spread="1.15"/>
                    <measurement group_id="O6" value="0.2" spread="1.01"/>
                    <measurement group_id="O7" value="0.2" spread="1.18"/>
                    <measurement group_id="O8" value="-0.4" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSQI Global Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.18"/>
                    <measurement group_id="O2" value="-0.3" spread="2.46"/>
                    <measurement group_id="O3" value="-0.3" spread="2.81"/>
                    <measurement group_id="O4" value="-0.8" spread="2.43"/>
                    <measurement group_id="O5" value="-0.9" spread="2.92"/>
                    <measurement group_id="O6" value="-1.0" spread="2.57"/>
                    <measurement group_id="O7" value="-1.0" spread="2.44"/>
                    <measurement group_id="O8" value="-0.1" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Change From Screening to Week 24 in the Epworth Sleepiness Scale (ESS) Total Score - Evaluable Population</title>
        <description>The Epworth Sleepiness Scale (ESS) is an eight-item questionnaire that assesses sleep propensity in daily situations of increasing sleepiness on a four-point scale with 0=would never doze and 3=high chance of dozing. Lower scores indicate improvement. Values were obtained for this questionnaire on Visit 3 in the screening period</description>
        <time_frame>Screening to Week 24</time_frame>
        <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Missing item responses may be imputed for each subject as appropriate before summarization.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change From Screening to Week 24 in the Epworth Sleepiness Scale (ESS) Total Score - Evaluable Population</title>
          <description>The Epworth Sleepiness Scale (ESS) is an eight-item questionnaire that assesses sleep propensity in daily situations of increasing sleepiness on a four-point scale with 0=would never doze and 3=high chance of dozing. Lower scores indicate improvement. Values were obtained for this questionnaire on Visit 3 in the screening period</description>
          <population>Evaluable population includes participants received at least one dose of randomized treatment, had adequate exposure to treatment, and complied with the protocol as assessed prior to database lock and unblinding. Missing item responses may be imputed for each subject as appropriate before summarization.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="44"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.552"/>
                    <measurement group_id="O2" value="-0.63" spread="0.450"/>
                    <measurement group_id="O3" value="0.12" spread="0.621"/>
                    <measurement group_id="O4" value="-1.32" spread="0.319"/>
                    <measurement group_id="O5" value="-1.80" spread="0.426"/>
                    <measurement group_id="O6" value="-1.05" spread="0.662"/>
                    <measurement group_id="O7" value="-1.80" spread="0.448"/>
                    <measurement group_id="O8" value="-0.42" spread="0.522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hematology and Urinalysis Laboratory Values of Potential Clinical Importance Observed From Screening to Week 28 - Intent to Treat Population</title>
        <description>Criteria for laboratory values of potential clinical importance for obese and overweight (BMI &gt;= 25 kg/m^2) participants: Platelets high (H) &gt;500,000/µL; low (L) &lt;75,000/µL. Hematocrit males &lt;36%, females &lt;30%. Hemoglobin males &lt;12 g/dL, females &lt;10 g/dL. White blood cell count (WBC) H &gt;18,000/µL; L &lt;1,500/µL. Urine protein H &gt;= 3+ or &gt;= 500 mg/dL. Urine glucose H &gt;= 3+ or &gt;= 500 mg/dL. Urine ketones &gt;= 3+ or Large. Values obtained at Screening, Day -7, Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28. Numbers of values are cumulative across the study.</description>
        <time_frame>Screening to Week 28</time_frame>
        <population>Intent to treat population included all randomized participants who received at least one injection of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered twice a day (BID) for 28 weeks, subcutaneous (SC) placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hematology and Urinalysis Laboratory Values of Potential Clinical Importance Observed From Screening to Week 28 - Intent to Treat Population</title>
          <description>Criteria for laboratory values of potential clinical importance for obese and overweight (BMI &gt;= 25 kg/m^2) participants: Platelets high (H) &gt;500,000/µL; low (L) &lt;75,000/µL. Hematocrit males &lt;36%, females &lt;30%. Hemoglobin males &lt;12 g/dL, females &lt;10 g/dL. White blood cell count (WBC) H &gt;18,000/µL; L &lt;1,500/µL. Urine protein H &gt;= 3+ or &gt;= 500 mg/dL. Urine glucose H &gt;= 3+ or &gt;= 500 mg/dL. Urine ketones &gt;= 3+ or Large. Values obtained at Screening, Day -7, Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28. Numbers of values are cumulative across the study.</description>
          <population>Intent to treat population included all randomized participants who received at least one injection of study medication.</population>
          <units>Number of Laboratory Values</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="78"/>
                <count group_id="O7" value="78"/>
                <count group_id="O8" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Ketones</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Chemistry Laboratory Values of Potential Clinical Importance Observed From Screening to Week 28 - Intent to Treat Population</title>
        <description>Obtained at: Screening, Days -7, 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28. Numbers of laboratory values are cumulative across the study. Criteria for values of potential clinical importance for obese and overweight (BMI&gt;=25 kg/m^2) participants: Total bilirubin High (H) &gt; 2 mg/dL; Plasma/serum glucose fasting or non-fasting H &gt; 200 mg/dL, low (L) &lt; 60 mg/dL; Albumin L &lt;2.5 g/dL; Creatine kinase H &gt; 3*Upper limit of Normal (ULN); Sodium L &lt;130 milliequivalents per liter (mEq/L), H &gt; 150 mEq/L; potassium L&lt;3.0 mEq/L, H&gt; 5.5 mEq/L;bicarbonate L&lt;18 mEq/L, H&gt;35 mEq/L;calcium L &lt;8mg/dL, H&gt; 11 mg/dL; triglycerides H&gt; 500 mg/dL; Cholesterol L &lt; 100 mg/dL, H &gt; 350 mg/dL; Alkaline phosphatase H &gt; 3*ULN; Gamma-glutamyltransferase H&gt;3*ULN; creatinine males &gt; 1.6 mg/dL, females &gt; 1.4 mg/dL; alanine aminotransferase H &gt; 3*ULN; aspartate aminotransferase H &gt; 3*ULN; urea nitrogen H &gt; 45 mg/dL; uric acid males &gt; 10.0 mg/dL, females &gt; 8.0 mg/dL; Phosphorus L &lt; 1.0 mg/dL H &gt; 6.0 mg/dL.</description>
        <time_frame>Screening to Week 28</time_frame>
        <population>Intent to treat population included all randomized participants who received at least one injection of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered twice a day (BID) for 28 weeks, subcutaneous (SC) placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Chemistry Laboratory Values of Potential Clinical Importance Observed From Screening to Week 28 - Intent to Treat Population</title>
          <description>Obtained at: Screening, Days -7, 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28. Numbers of laboratory values are cumulative across the study. Criteria for values of potential clinical importance for obese and overweight (BMI&gt;=25 kg/m^2) participants: Total bilirubin High (H) &gt; 2 mg/dL; Plasma/serum glucose fasting or non-fasting H &gt; 200 mg/dL, low (L) &lt; 60 mg/dL; Albumin L &lt;2.5 g/dL; Creatine kinase H &gt; 3*Upper limit of Normal (ULN); Sodium L &lt;130 milliequivalents per liter (mEq/L), H &gt; 150 mEq/L; potassium L&lt;3.0 mEq/L, H&gt; 5.5 mEq/L;bicarbonate L&lt;18 mEq/L, H&gt;35 mEq/L;calcium L &lt;8mg/dL, H&gt; 11 mg/dL; triglycerides H&gt; 500 mg/dL; Cholesterol L &lt; 100 mg/dL, H &gt; 350 mg/dL; Alkaline phosphatase H &gt; 3*ULN; Gamma-glutamyltransferase H&gt;3*ULN; creatinine males &gt; 1.6 mg/dL, females &gt; 1.4 mg/dL; alanine aminotransferase H &gt; 3*ULN; aspartate aminotransferase H &gt; 3*ULN; urea nitrogen H &gt; 45 mg/dL; uric acid males &gt; 10.0 mg/dL, females &gt; 8.0 mg/dL; Phosphorus L &lt; 1.0 mg/dL H &gt; 6.0 mg/dL.</description>
          <population>Intent to treat population included all randomized participants who received at least one injection of study medication.</population>
          <units>Number of Laboratory Values</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="78"/>
                <count group_id="O7" value="78"/>
                <count group_id="O8" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>alanine aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aspartate aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma-glutamyltransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Systolic and Diastolic Blood Pressure From Baseline to Week 28 - Intent to Treat Population</title>
        <description>Baseline refers to Day 1. If Day 1 value was missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 was used. Blood pressure was taken while the participant was sitting and was measured in millimeters of mercury (mm Hg). Values obtained at Screening, Day -7, Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28</description>
        <time_frame>Baseline to Week 28</time_frame>
        <population>Intent to treat population included all randomized participants who received at least one injection of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered twice a day (BID) for 28 weeks, subcutaneous (SC) placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Systolic and Diastolic Blood Pressure From Baseline to Week 28 - Intent to Treat Population</title>
          <description>Baseline refers to Day 1. If Day 1 value was missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 was used. Blood pressure was taken while the participant was sitting and was measured in millimeters of mercury (mm Hg). Values obtained at Screening, Day -7, Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28</description>
          <population>Intent to treat population included all randomized participants who received at least one injection of study medication.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="78"/>
                <count group_id="O7" value="78"/>
                <count group_id="O8" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="10.65"/>
                    <measurement group_id="O2" value="-0.9" spread="11.9"/>
                    <measurement group_id="O3" value="-3.4" spread="12.54"/>
                    <measurement group_id="O4" value="-3.2" spread="10.84"/>
                    <measurement group_id="O5" value="0.4" spread="11.84"/>
                    <measurement group_id="O6" value="-2.0" spread="12.47"/>
                    <measurement group_id="O7" value="-1.2" spread="10.78"/>
                    <measurement group_id="O8" value="-1.5" spread="12.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="7.31"/>
                    <measurement group_id="O2" value="-1.7" spread="6.83"/>
                    <measurement group_id="O3" value="-2.6" spread="7.21"/>
                    <measurement group_id="O4" value="-0.4" spread="8.07"/>
                    <measurement group_id="O5" value="-1.0" spread="6.99"/>
                    <measurement group_id="O6" value="-1.3" spread="7.96"/>
                    <measurement group_id="O7" value="-1.8" spread="6.77"/>
                    <measurement group_id="O8" value="-0.1" spread="9.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Heart Rate From Baseline to Week 28 - Intent to Treat Population</title>
        <description>Baseline refers to Day 1. If Day 1 value was missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 was used. Heart rate was measured while the participant was sitting and was measured in beats per minute (bpm). Values obtained at Screening, Day -7, Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28.</description>
        <time_frame>Baseline to Week 28</time_frame>
        <population>Intent to treat population included all randomized participants who received at least one injection of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered twice a day (BID) for 28 weeks, subcutaneous (SC) placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Heart Rate From Baseline to Week 28 - Intent to Treat Population</title>
          <description>Baseline refers to Day 1. If Day 1 value was missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 was used. Heart rate was measured while the participant was sitting and was measured in beats per minute (bpm). Values obtained at Screening, Day -7, Day 1, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28.</description>
          <population>Intent to treat population included all randomized participants who received at least one injection of study medication.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="78"/>
                <count group_id="O6" value="78"/>
                <count group_id="O7" value="78"/>
                <count group_id="O8" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="9.29"/>
                    <measurement group_id="O2" value="-1.3" spread="7.70"/>
                    <measurement group_id="O3" value="-2.6" spread="6.66"/>
                    <measurement group_id="O4" value="-1.4" spread="8.40"/>
                    <measurement group_id="O5" value="-2.1" spread="7.38"/>
                    <measurement group_id="O6" value="-0.5" spread="9.34"/>
                    <measurement group_id="O7" value="-2.4" spread="7.54"/>
                    <measurement group_id="O8" value="-0.1" spread="10.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Positive Anti-leptin Antibody Titers at Week 28 - Intent to Treat Population</title>
        <description>Baseline refers to Day 1. If Day 1 value was missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 was used. Serum titer determinations for antibodies to metreleptin were made using a validated electrochemical luminescence (ECLA) bridging assay. Antibody titers were assessed according to the following dilutions: 0, 5, 25, 125, 625, 3125, 15625, and 78125. Participants were considered to have a positive titer to treatment-emergent antibodies to metreleptin at a given visit if they had a titer &gt;=5 following a negative or missing titer at baseline or if they had a titer that had increased by at least 2 dilutions from a detectable level at baseline.</description>
        <time_frame>Baseline to Week 28</time_frame>
        <population>Intent to treat population included all randomized participants who received at least one injection of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O3">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Positive Anti-leptin Antibody Titers at Week 28 - Intent to Treat Population</title>
          <description>Baseline refers to Day 1. If Day 1 value was missing or after the first dose date of randomized study medication, the last available value on or prior to Day 1 was used. Serum titer determinations for antibodies to metreleptin were made using a validated electrochemical luminescence (ECLA) bridging assay. Antibody titers were assessed according to the following dilutions: 0, 5, 25, 125, 625, 3125, 15625, and 78125. Participants were considered to have a positive titer to treatment-emergent antibodies to metreleptin at a given visit if they had a titer &gt;=5 following a negative or missing titer at baseline or if they had a titer that had increased by at least 2 dilutions from a detectable level at baseline.</description>
          <population>Intent to treat population included all randomized participants who received at least one injection of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Screening to Week 28 in Electrocardiogram Parameters - Intent to Treat Population</title>
        <description>A 12-Lead electrocardiogram (ECG) was obtained at Screening, Day 1, Weeks 1, 12, 28 (study termination). The PR interval, which is time from beginning of the P wave to the beginning of the QRS complex (Note: QRS complex is a name for the combination of 3 of the graphical deflections seen in an ECG); QRS interval (time from the beginning to the end of the QRS complex); QT interval (measure between Q wave and T wave in the heart's electrical cycle); and QT interval corrected for heart rate using Fridericia's formula (QTcF) were measured in milliseconds (msec).</description>
        <time_frame>Screening to Week 28 (or study termination)</time_frame>
        <population>Intent to treat population included all randomized participants who received at least one injection of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered twice a day (BID) for 28 weeks, subcutaneous (SC) placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Screening to Week 28 in Electrocardiogram Parameters - Intent to Treat Population</title>
          <description>A 12-Lead electrocardiogram (ECG) was obtained at Screening, Day 1, Weeks 1, 12, 28 (study termination). The PR interval, which is time from beginning of the P wave to the beginning of the QRS complex (Note: QRS complex is a name for the combination of 3 of the graphical deflections seen in an ECG); QRS interval (time from the beginning to the end of the QRS complex); QT interval (measure between Q wave and T wave in the heart's electrical cycle); and QT interval corrected for heart rate using Fridericia's formula (QTcF) were measured in milliseconds (msec).</description>
          <population>Intent to treat population included all randomized participants who received at least one injection of study medication.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="44"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="12.73"/>
                    <measurement group_id="O2" value="-0.1" spread="12.23"/>
                    <measurement group_id="O3" value="0.3" spread="10.37"/>
                    <measurement group_id="O4" value="0.1" spread="13.74"/>
                    <measurement group_id="O5" value="16.8" spread="97.51"/>
                    <measurement group_id="O6" value="4.4" spread="17.89"/>
                    <measurement group_id="O7" value="0.4" spread="11.86"/>
                    <measurement group_id="O8" value="-1.6" spread="14.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="5.20"/>
                    <measurement group_id="O2" value="-1.4" spread="8.76"/>
                    <measurement group_id="O3" value="1.0" spread="4.66"/>
                    <measurement group_id="O4" value="-0.5" spread="6.26"/>
                    <measurement group_id="O5" value="-1.8" spread="5.62"/>
                    <measurement group_id="O6" value="-0.2" spread="4.12"/>
                    <measurement group_id="O7" value="0.3" spread="4.78"/>
                    <measurement group_id="O8" value="-0.4" spread="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="28.72"/>
                    <measurement group_id="O2" value="9.9" spread="21.80"/>
                    <measurement group_id="O3" value="16.2" spread="28.64"/>
                    <measurement group_id="O4" value="7.0" spread="19.33"/>
                    <measurement group_id="O5" value="8.9" spread="20.53"/>
                    <measurement group_id="O6" value="4.4" spread="24.97"/>
                    <measurement group_id="O7" value="15.0" spread="21.56"/>
                    <measurement group_id="O8" value="6.3" spread="28.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="21.75"/>
                    <measurement group_id="O2" value="4.0" spread="15.58"/>
                    <measurement group_id="O3" value="8.2" spread="21.39"/>
                    <measurement group_id="O4" value="-1.2" spread="16.02"/>
                    <measurement group_id="O5" value="-0.8" spread="15.13"/>
                    <measurement group_id="O6" value="0.3" spread="15.40"/>
                    <measurement group_id="O7" value="1.3" spread="12.34"/>
                    <measurement group_id="O8" value="-2.3" spread="22.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Screening to Week 28 in the Electrocardiogram Parameter of Heart Rate - Intent to Treat Population</title>
        <description>A 12-Lead electrocardiogram (ECG) was obtained at Screening (visit 2), Day 1, Weeks 1, 12, 28 (study termination). Heart Rate was measured in beats per min (bpm).</description>
        <time_frame>Screening to Week 28 (or early termination)</time_frame>
        <population>Intent to treat population included all randomized participants who received at least one injection of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Self administered twice a day (BID) for 28 weeks, subcutaneous (SC) placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
          </group>
          <group group_id="O2">
            <title>Pramlintide 360 mcg</title>
            <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O3">
            <title>Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
          </group>
          <group group_id="O4">
            <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
          </group>
          <group group_id="O5">
            <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
          </group>
          <group group_id="O6">
            <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O7">
            <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
          <group group_id="O8">
            <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
            <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Screening to Week 28 in the Electrocardiogram Parameter of Heart Rate - Intent to Treat Population</title>
          <description>A 12-Lead electrocardiogram (ECG) was obtained at Screening (visit 2), Day 1, Weeks 1, 12, 28 (study termination). Heart Rate was measured in beats per min (bpm).</description>
          <population>Intent to treat population included all randomized participants who received at least one injection of study medication.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="44"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="13.96"/>
                    <measurement group_id="O2" value="-2.8" spread="8.45"/>
                    <measurement group_id="O3" value="-4.1" spread="8.18"/>
                    <measurement group_id="O4" value="-4.7" spread="10.12"/>
                    <measurement group_id="O5" value="-4.9" spread="9.42"/>
                    <measurement group_id="O6" value="-1.9" spread="9.73"/>
                    <measurement group_id="O7" value="-6.6" spread="8.41"/>
                    <measurement group_id="O8" value="-3.4" spread="9.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment to Study Termination (Week 28). Clinically significant events that continued beyond termination were followed until diagnosis/resolution occurred. Serious adverse events were followed 30 days post last dose of study medication.</time_frame>
      <desc>All participants enrolled were treated with Placebo for 1 week and then randomized into a treatment group. Enrolled = 636 (commenced placebo for 1 week); Enrolled but not randomized = 28; Randomized = 608; Intent to treat = Randomized and received at least 1 dose. Events presented below from Randomized population, treatment-emergent (ITT).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Self administered BID for 28 weeks, SC placebo matched to pramlintide (Placebo-P) plus SC placebo matched to metreleptin (Placebo-M).</description>
        </group>
        <group group_id="E2">
          <title>Pramlintide 360 mcg</title>
          <description>Self administered BID for 28 weeks, SC 360 mcg pramlintide acetate plus SC Placebo matched to Metreleptin (Placebo-M). The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
        </group>
        <group group_id="E3">
          <title>Metreleptin 5.0 mg</title>
          <description>Self administered BID for 28 weeks, SC metreleptin 5.0 mg plus SC Placebo matched to pramlintide (Placebo-P).</description>
        </group>
        <group group_id="E4">
          <title>Pramlintide 180 mcg + Metreleptin 2.5 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 2.5 mg.</description>
        </group>
        <group group_id="E5">
          <title>Pramlintide 180 mcg + Metreleptin 5.0 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 180 mcg plus SC Metreleptin 5.0 mg.</description>
        </group>
        <group group_id="E6">
          <title>Pramlintide 360 mcg + Metreleptin 1.25 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 1.25 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
        </group>
        <group group_id="E7">
          <title>Pramlintide 360 mcg + Metreleptin 2.5 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 2.5 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
        </group>
        <group group_id="E8">
          <title>Pramlintide 360 mcg + Metreleptin 5.0 mg</title>
          <description>Self administered BID for 28 weeks, SC Pramlintide 360 mcg plus SC Metreleptin 5.0 mg. The first week of the 28 weeks started with a lower pramlintide dose (180 mcg) in a blinded fashion (using 2 different concentrations of pramlintide so the dose change was not apparent to the participant).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goiter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food Allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Parathyroid Tumor benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="71" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="68" subjects_at_risk="78"/>
                <counts group_id="E7" subjects_affected="72" subjects_at_risk="78"/>
                <counts group_id="E8" subjects_affected="68" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="37" subjects_affected="31" subjects_at_risk="77"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E4" events="30" subjects_affected="27" subjects_at_risk="75"/>
                <counts group_id="E5" events="22" subjects_affected="21" subjects_at_risk="78"/>
                <counts group_id="E6" events="27" subjects_affected="26" subjects_at_risk="78"/>
                <counts group_id="E7" events="32" subjects_affected="29" subjects_at_risk="78"/>
                <counts group_id="E8" events="20" subjects_affected="19" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E3" events="25" subjects_affected="15" subjects_at_risk="72"/>
                <counts group_id="E4" events="17" subjects_affected="15" subjects_at_risk="75"/>
                <counts group_id="E5" events="21" subjects_affected="17" subjects_at_risk="78"/>
                <counts group_id="E6" events="9" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E7" events="25" subjects_affected="24" subjects_at_risk="78"/>
                <counts group_id="E8" events="24" subjects_affected="21" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>injection site pruritus</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" events="19" subjects_affected="13" subjects_at_risk="72"/>
                <counts group_id="E4" events="20" subjects_affected="19" subjects_at_risk="75"/>
                <counts group_id="E5" events="23" subjects_affected="21" subjects_at_risk="78"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E7" events="20" subjects_affected="18" subjects_at_risk="78"/>
                <counts group_id="E8" events="23" subjects_affected="22" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>injection site bruising</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="75"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="77"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E4" events="16" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="78"/>
                <counts group_id="E6" events="13" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E7" events="9" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E8" events="23" subjects_affected="16" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>injection site hemorrhage</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E3" events="17" subjects_affected="13" subjects_at_risk="72"/>
                <counts group_id="E4" events="17" subjects_affected="14" subjects_at_risk="75"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E7" events="11" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E8" events="12" subjects_affected="11" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>injection site urticaria</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="75"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" events="14" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E8" events="11" subjects_affected="11" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>injection site rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="72"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E6" events="12" subjects_affected="9" subjects_at_risk="78"/>
                <counts group_id="E7" events="12" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E8" events="10" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>injection site nodule</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E8" events="10" subjects_affected="8" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>injection site induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>injection site inflammation</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E7" events="13" subjects_affected="9" subjects_at_risk="78"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="9" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E8" events="7" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E5" events="13" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>sinus congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Drug Randomization stratified:sex,3 categories baseline BMI (12 arms); 3 treatment arms combined for summaries as single placebo treatment group; 3 combined for summaries as single pramlintide monotherapy treatment group (total:8 treatment groups).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Peter Ohman, Medical Science Director</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

